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DrAs I spent countless hours pouring over hundreds of manuscripts to select those that rose to the top over the past year,
I became incredibly excited about being part of a Journal that produces such wonderfully rich and diverse content each
year. I have personally selected the papers (both original investigations and review articles) from 13 distinct specialties
for your review. There are approximately 150 articles selected across this 2-part series, which represents less than 3% of
the papers submitted to JACC in 2014. In order to present the full breadth of this important research in a consumable
fashion, we will present these manuscripts over the course of 2 issues of JACC.
Part One includes the sections: Congenital Heart Disease, Coronary Disease & Interventions, Genetics, Omics, & Tissue
Regeneration, CV Prevention & Health Promotion, Cardiac Failure, and Cardiomyopathies (1–70). Part Two includes the
sections: Hypertension, Imaging, Metabolic Disorders & Lipids, Neurovascular & Neurodegenerative Disorders, Rhythm
Disorders, Valvular Heart Disease, and Vascular Medicine.CONGENITAL HEART DISEASE
Procedural Results and Safety of Common
Interventional Procedures in Congenital Heart
Disease: Initial Report From the National
Cardiovascular Data Registry
J.W. Moore, et al.
BACKGROUND The National Cardiovascular Data
Registry (NCDR) launched the IMPACT (Improving
Pediatric and Adult Congenital Treatment) Registry in
2010. By 2013, its patient enrollment exceeded that of
other current and historical congenital catheterization
registries.
OBJECTIVES This study sought to describe procedural
results and safety of 6 common congenital in-
terventions performed in patients enrolled during the
IMPACT Registry’s initial periods.
METHODS With speciﬁed exclusions, we compiled
registry data from patients enrolled in the IMPACT
Registry from January 2011 through March 2013 who
underwent 1 of the following isolated procedures: de-
vice closure of atrial septal defect (ASD); device closure
of patent ductus arteriosus (PDA); pulmonary valvulo-
plasty; aortic valvuloplasty; coarctation of the aorta
angioplasty and stenting; and pulmonary arteryten to this manuscript’s audio summary by JACC Editor-in-Chief
. Valentin Fuster.
u can also listen to this issue’s audio summary by JACC Editor-in-Chief
. Valentin Fuster.stenting. Patient data, procedural data and results, and
adverse events (AEs) were reviewed and described.
RESULTS In 4,152 catheterizations, 1 isolated procedure
was reported. There were 1,286 single-ASD procedures,
1,375 PDA procedures, 270 “typical” pulmonary valve
procedures, 305 aortic valve procedures, 671 aortic
procedures, and 245 pulmonary artery procedures. The
reported procedure was performed in >95% of
catheterizations. Stated outcomes were accomplished in
>98% of ASD and PDA procedures, but less commonly
in the others, with coarctation angioplasty procedures
being the least successful (51%). Reported major AE
rates ranged from 0% to 3.3%; total AE rates ranged
from 5.3% to 24.3%.
CONCLUSIONS Contemporary community practice,
procedural outcomes, and safety for 6 common
congenital interventional procedures are reported.
These benchmarks may be compared with individual
center results and historical single-center and
multicenter results (1).
Low Risk of Pulmonary Valve Implantation After
a Policy of Transatrial Repair of Tetralogy of
Fallot Delayed Beyond the Neonatal Period:
The Melbourne Experience Over 25 Years
Y. d’Udekem, et al.
OBJECTIVES The study sought to evaluate the late
outcomes of a policy of transatrial repair delayed
beyond the neonatal period.
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587BACKGROUND Long-term outcomes of transatrial
repair of tetralogy of Fallot are unknown.
METHODS The records of 675 consecutive patients
undergoing a transatrial repair of tetralogy of Fallot
between 1980 and 2005 were reviewed, their follow-
up updated and survival conﬁrmed from national
death registries. One-third (220 of 675) had
undergone previous palliation. Median age at repair
was 2 years in the ﬁrst 8 years, and 1 year from 1988
onward. A transannular incision was performed in
75% of cases and autologous pericardium was the
material used to patch this incision in 92% of cases.
RESULTS There were 7 hospital deaths (1%). Eight pa-
tients died during follow-up (2 sudden unexpected and
6 noncardiac deaths). Mean follow-up was 11.7  6.3
years. Twenty-ﬁve years’ survival was 97% (95%
conﬁdence interval [CI]: 95% to 98%). Twenty-ﬁve
years’ freedom from implantation of a valved conduit
was 84.6% (95% CI: 77.8% to 89.5%). By multivariable
analysis, prior palliation and younger age at repair
were predictive of implantation of a valved conduit
(hazard ratio: 2.4, 95% CI: 1.3 to 4.6, p ¼ 0.008; hazard
ratio: 0.70, 95% CI: 0.50 to 0.96, p¼ 0.03, respectively).
CONCLUSIONS During long-term follow-up, transatrial
repair of tetralogy of Fallot was associated with a
minimal risk of sudden death and low rate of re-
intervention for right ventricular dilation and residual
outﬂow tract obstruction (2).
D-Transposition of the Great Arteries: The
Current Era of the Arterial Switch Operation
J. Villafañe, et al.
This paper aims to update clinicians on “hot topics” in
the management of patients with D-loop transposition
of the great arteries (D-TGA) in the current surgical era.
The arterial switch operation (ASO) has replaced atrial
switch procedures for D-TGA, and 90% of patients
now reach adulthood. The Adult Congenital and
Pediatric Cardiology Council of the American College
of Cardiology assembled a team of experts to
summarize current knowledge on genetics, pre-natal
diagnosis, surgical timing, balloon atrial septostomy,
prostaglandin E1 therapy, intraoperative techniques,
imaging, coronary obstruction, arrhythmias, sudden
death, neoaortic regurgitation and dilation, neu-
rodevelopmental (ND) issues, and lifelong care of
D-TGA patients. In simple D-TGA: 1) familial recurrence
risk is low; 2) children diagnosed pre-natally have
improved cognitive skills compared with those
diagnosed post-natally; 3) echocardiography helps to
identify risk factors; 4) routine use of BAS and
prostaglandin E1 may not be indicated in all cases; 5)early ASO improves outcomes and reduces costs with a
low mortality; 6) single or intramural coronary arteries
remain risk factors; 7) post-ASO arrhythmias and
cardiac dysfunction should raise suspicion of
coronary insufﬁciency; 8) coronary insufﬁciency and
arrhythmias are rare but are associated with sudden
death; 9) early- and late-onset ND abnormalities are
common; 10) aortic regurgitation and aortic root
dilation are well tolerated; and 11) the aging ASO
patient may beneﬁt from “exercise-prescription”
rather than restriction. Signiﬁcant strides have been
made in understanding risk factors for cardiac, ND, and
other important clinical outcomes after ASO (3).
Survival Differences in Pediatric Pulmonary
Arterial Hypertension: Clues to a Better
Understanding of Outcome and Optimal
Treatment Strategies
W.M.H. Zijlstra, et al.
OBJECTIVES In order to describe survival and treat-
ment strategies in pediatric pulmonary arterial
hypertension (PAH) in the current era of PAH-targeted
drugs and to identify predictors of outcome, we
studied uniformly deﬁned contemporary patient
cohorts at 3 major referral centers for pediatric PAH
(New York [NY], Denver, and the Netherlands [NL]).
BACKGROUND In pediatric PAH, discrepancies exist
in reported survival rates between North American
and European patient cohorts, and robust data for
long-term treatment effects are lacking.
METHODS According to uniform inclusion criteria, 275
recently diagnosed consecutive pediatric PAH patients
who visited the 3 referral centers between 2000 and
2010 were included.
RESULTS Unadjusted survival rates differed between
the center cohorts (1-, 3-, and 5-year transplantation-free
survival rates: 100%, 96%, and 90% for NY; 95%, 87%,
and 78% for Denver; and 84%, 71%, and 62% for NL,
respectively; p < 0.001). Based on World Health
Organization (WHO) functional class and hemodynamic
parameters, disease severity at diagnosis differed
between the center cohorts. Adjustment for diagnosis,
WHO functional class, indexed pulmonary vascular
resistance, and pulmonary-to-systemic arterial pressure
ratio resolved the observed survival differences.
Treatment with PAH-targeted dual and triple therapy
during the study period was associated with better
survival than treatmentwithPAH-targetedmonotherapy.
CONCLUSIONS Survival rates of pediatric PAHpatients
differed between 3major referral centers. This could be
explained by differences between the center cohorts in
patients’ diagnoses and measures of disease severity,
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588which were identiﬁed as important predictors of
outcome. In this study, treatment with PAH-targeted
combination therapy during the study period was
independently associated with improved survival (4).
Clinical Outcomes and Improved Survival in
Patients With Protein-Losing Enteropathy After
the Fontan Operation
A.S. John, et al.
BACKGROUND Patients with protein-losing entero-
pathy (PLE) following the Fontan operation have a
reported 50% mortality at 5 years after diagnosis.
OBJECTIVES The aim of this study was to review
outcomes in patients with PLE following the Fontan
operation.
METHODS From 1992 to 2010, 42 patients (55% male)
with PLE following the Fontan operation were iden-
tiﬁed from clinical databases at the Mayo Clinic. Data
were collected retrospectively.
RESULTS Mean age at PLE diagnosis was 18.9  11.0
years. Initial Fontan operation was performed at 10.1 
10.8 years of age. Mean time from Fontan operation to
PLE diagnosis was 8.4 14.2 years. Survival was 88% at
5 years. Decreased survival was seen in patients with
high Fontan pressure (mean >15 mm Hg; p ¼ 0.04),
decreased ventricular function (ejection fraction<55%;
p ¼ 0.03), and New York Heart Association functional
class >2 at diagnosis (p ¼ 0.04). Patients who died had
higher pulmonary vascular resistance (3.8  1.6 Wood
units [WU] vs. 2.1  1.1 WU; p ¼ 0.017), lower cardiac
index (1.6  0.4 l/min/m2 vs. 2.7  0.7 l/min/m2; p <
0.0001), and lower mixed venous saturation (53% vs.
66%; p ¼ 0.01), compared with survivors. Factors were
assessed at the time of PLE diagnosis. Treatments used
more frequently in survivors with PLE included spi-
ronolactone (21 [68%]), octreotide (7 [21%]), sildenaﬁl
(6 [19%]), fenestration creation (15 [48%]), and relief of
Fontan obstruction (7 [23%]).
CONCLUSIONS PLE remains difﬁcult to treat; howev-
er, in the current era, survival has improved with ad-
vances in treatment. Further study is needed to better
understand the mechanism of disease and ideal
treatment strategy (5).CORONARY DISEASE & INTERVENTIONS
The Year in Acute Coronary Syndrome
R.P. Giugliano, et al.
In this year’s report on acute coronary syndromes (ACS),
we have expanded the scope to include ST-segment
elevation myocardial infarction (STEMI) in addition tonon–ST-segment elevation ACS. In this report, we
review selected highlights across the spectrum of ACS
published between June 2012 and September 2013 (6).
Undetectable High-Sensitivity Cardiac Troponin T
Level in the Emergency Department and Risk of
Myocardial Infarction
N. Bandstein, et al.
OBJECTIVES This study sought to evaluate if an un-
detectable (<5 ng/l) high-sensitivity cardiac troponin
T (hs-cTnT) level and an electrocardiogram (ECG)
without signs of ischemia can rule out myocardial
infarction (MI) in the emergency department (ED).
BACKGROUND Chest pain is a common symptom
often associated with benign conditions, but may be a
sign of MI. Because there is no rapid way to rule out
MI, many patients are admitted to the hospital.
METHODS All patients who sought medical attention
for chest pain and had at least 1 hs-cTnT analyzed
during 2 years at the Karolinska University Hospital,
Stockholm, Sweden, were included. We calculated
the negative predictive values of an undetectable hs-
cTnT and ECG without ischemia for MI and death
within 30 days.
RESULTS We included 14,636 patients, of whom 8,907
(61%) had an initial hs-cTnT of <5 ng/l; 21% had 5 to 14
ng/l, and 18%had>14 ng/l. During 30-day follow-up, 39
(0.44%) patients with undetectable hs-cTnT had a MI,
of whom 15 (0.17%) had no ischemic ECG changes.
The negative predictive value for MI within 30 days in
patients with undetectable hs-cTnT and no ischemic
ECG changes was 99.8% (95% conﬁdence interval [CI]:
99.7 to 99.9). The negative predictive value for death
was 100% (95% CI: 99.9 to 100).
CONCLUSIONS All patients with chest pain who have
an initial hs-cTnT level of <5 ng/l and no signs of
ischemia on an ECG have a minimal risk of MI or
death within 30 days, and can be safely discharged
directly from the ED (7).
Long-Term Beneﬁt of Early Pre-Reperfusion
Metoprolol Administration in Patients With
Acute Myocardial Infarction: Results From the
METOCARD-CNIC Trial (Effect of Metoprolol in
Cardioprotection During an Acute Myocardial
Infarction)
G. Pizarro, et al.
OBJECTIVES The goal of this trial was to study the
long-term effects of intravenous (IV) metoprolol
administration before reperfusion on left ventricular
(LV) function and clinical events.
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589BACKGROUND Early IV metoprolol during ST-
segment elevation myocardial infarction (STEMI) has
been shown to reduce infarct size when used in
conjunction with primary percutaneous coronary
intervention (pPCI).
METHODS The METOCARD-CNIC (Effect of Metopro-
lol in Cardioprotection During an Acute Myocardial
Infarction) trial recruited 270 patients with Killip
class #II anterior STEMI presenting early after
symptom onset (<6 h) and randomized them to pre-
reperfusion IV metoprolol or control group. Long-
term magnetic resonance imaging (MRI) was
performed on 202 patients (101 per group) 6 months
after STEMI. Patients had a minimal 12-month
clinical follow-up.
RESULTS Left ventricular ejection fraction (LVEF) at
the 6 months MRI was higher after IV metoprolol (48.7
 9.9% vs. 45.0  11.7% in control subjects; adjusted
treatment effect 3.49%; 95% conﬁdence interval [CI]:
0.44% to 6.55%; p ¼ 0.025). The occurrence of
severely depressed LVEF (#35%) at 6 months was
signiﬁcantly lower in patients treated with IV meto-
prolol (11% vs. 27%, p ¼ 0.006). The proportion of
patients fulﬁlling Class I indications for an implant-
able cardioverter-deﬁbrillator (ICD) was signiﬁcantly
lower in the IV metoprolol group (7% vs. 20%, p ¼
0.012). At a median follow-up of 2 years, occurrence
of the pre-speciﬁed composite of death, heart failure
admission, reinfarction, and malignant arrhythmias
was 10.8% in the IV metoprolol group versus 18.3%
in the control group, adjusted hazard ratio (HR):
0.55; 95% CI: 0.26 to 1.04; p ¼ 0.065. Heart failure
admission was signiﬁcantly lower in the IV
metoprolol group (HR: 0.32; 95% CI: 0.015 to 0.95;
p ¼ 0.046).
CONCLUSIONS In patients with anterior Killip class #II
STEMI undergoing pPCI, early IV metoprolol before
reperfusion resulted in higher long-term LVEF, reduced
incidence of severe LV systolic dysfunction and ICD
indications, and fewer heart failure admissions. (Effect
of METOprolol in CARDioproteCtioN During an Acute
Myocardial InfarCtion. The METOCARD-CNIC Trial;
NCT01311700) (8).
Short- and Long-Term Cause of Death in Patients
Treated With Primary PCI for STEMI
F. Pedersen, et al.
BACKGROUND Short-term mortality has been studied
thoroughly in patients undergoing primary percuta-
neous coronary intervention (PCI), whereas long-term
cause of death in patients with ST-segment elevation
myocardial infarction (STEMI) remains unknown.OBJECTIVES The goal of this study was to describe
the association between time and cause of death in
patients with STEMI undergoing primary PCI.
METHODS A centralized civil registration system, pa-
tient ﬁles, and public disease and death cause regis-
tries with an accurate record linkage were used to
trace time and cause of death in 2,804 consecutive
patients with STEMI (age 63  13 years, 72% males)
treated with primary PCI.
RESULTS Patients were followed up for a median of
4.7 years. During a total of 13,447 patient-years, 717
patients died. Main causes of death within the ﬁrst
30 days were cardiogenic shock and anoxic brain
injury after cardiac arrest. Age, culprit vessel size
and ﬂow, and the presence of heart failure and
diabetes were independent predictors of mortality.
After 30 days, the annual cardiac mortality rate
was <1.5%. Causes of death beyond 30 days were
noncardiac in 65% of cases (mainly malignancies and
pulmonary diseases). The 30-day, 1-year, and 5-year
all-cause (and cardiac) mortality rates were 7.9%
(7.3%), 11.4% (8.4%), and 23.3% (13.8%), respectively.
CONCLUSIONS Patients who survive the ﬁrst month
after an STEMI treated with primary PCI have an
excellent prognosis, with a <1.5% annual risk of suc-
cessive cardiac death. Noncardiac causes are re-
sponsible for the majority of later deaths in these
patients (9).
A Polypill Strategy to Improve Global Secondary
Cardiovascular Prevention: From Concept to
Reality
J.M. Castellano, et al.
The prevention of cardiovascular disease (CVD) by using
a polypill has gained increasing momentum as a strategy
to contain progression of the disease. Since its initial
conception just over a decade ago, only a handful of
trials have been completed assessing the efﬁcacy and
safety of this innovative concept. The results of these
trials have supported the viability of the polypill in
CVD prevention and management, albeit with a few
caveats, essentially related to the lack of evidence on
the effect of the polypill to effectively reduce
cardiovascular events. The polypill has the potential to
control the global health epidemic of CVD by
effectively reaching underdeveloped regions of the
world, simplifying healthcare delivery, improving cost-
effectiveness, increasing medication adherence, and
supporting a comprehensive prescription of evidence-
based cardioprotective drugs. Major trials underway
will provide deﬁnitive evidence on the efﬁcacy of
the polypill in reducing cardiovascular events in a
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590cost-effective manner. The results of these studies will
determine whether a polypill strategy can quell the
burgeoning public health challenge of CVD and will
potentially provide the evidence to implement an
effective, simple, and innovative solution to restrain
the global CVD pandemic (10).
Prognostic Value of Fractional Flow Reserve:
Linking Physiologic Severity to Clinical Outcomes
N.P. Johnson, et al.
BACKGROUND Fractional ﬂow reserve (FFR) has
become an established tool for guiding treatment, but
its graded relationship to clinical outcomes as modu-
lated by medical therapy versus revascularization re-
mains unclear.
OBJECTIVES The study hypothesized that FFR dis-
plays a continuous relationship between its numeric
value and prognosis, such that lower FFR values
confer a higher risk and therefore receive larger ab-
solute beneﬁts from revascularization.
METHODS Meta-analysis of study- and patient-level
data investigated prognosis after FFR measurement.
An interaction term between FFR and revascularization
status allowed for an outcomes-based threshold.
RESULTS A total of 9,173 (study-level) and 6,961 (pa-
tient-level) lesions were included with a median follow-
up of 16 and 14 months, respectively. Clinical events
increased as FFR decreased, and revascularization
showed larger net beneﬁt for lower baseline FFR
values. Outcomes-derived FFR thresholds generally
occurred around the range 0.75 to 0.80, although
limited due to confounding by indication. FFR
measured immediately after stenting also showed an
inverse relationship with prognosis (hazard ratio: 0.86,
95% conﬁdence interval: 0.80 to 0.93; p < 0.001).
An FFR-assisted strategy led to revascularization
roughly half as often as an anatomy-based strategy,
but with 20% fewer adverse events and 10% better
angina relief.
CONCLUSIONS FFR demonstrates a continuous and
independent relationship with subsequent outcomes,
modulated by medical therapy versus revasculariza-
tion. Lesions with lower FFR values receive larger
absolute beneﬁts from revascularization. Measure-
ment of FFR immediately after stenting also shows an
inverse gradient of risk, likely from residual diffuse
disease. An FFR-guided revascularization strategy
signiﬁcantly reduces events and increases freedom
from angina with fewer procedures than an
anatomy-based strategy (11).
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spact of Microvascular Obstruction on the
ssessment of Coronary Flow Reserve, Index
f Microcirculatory Resistance, and Fractional
low Reserve After ST-Segment Elevation
yocardial Infarction
. Cuculi, et al.
ACKGROUND Invasive assessment of coronary
hysiology (IACP) offers important prognostic in-
ights in ST-segment elevation myocardial infarction
TEMI) but the dynamics of coronary recovery are
oorly understood.
BJECTIVES This study sought to examine the evo-
tion of coronary ﬂow reserve (CFR), index of
icrocirculatory resistance (IMR), ratio of distal cor-
nary pressure (Pd) to mean aortic pressure (Pa), and
actional ﬂow reserve (FFR) in patients undergoing
rimary percutaneous coronary intervention (PPCI).
ETHODS 82 patients with STEMI underwent IACP at
PCI. Repeat IACP was performed in 61 patients (74%)
t day 1 and in 46 patients (56%) at 6 months.
ontrast-enhanced cardiac magnetic resonance
aging (CMR) was performed in 45 patients (55%) at
ay 1 and in 41 patients (50%) at 6 months. Changes
IACP were compared between patients with and
ithout microvascular obstruction (MVO) on CMR.
ESULTS MVO was present in 21 of 45 patients (47%).
atients with MVO had lower CFR at PPCI and day 1
< 0.05) and a trend toward higher IMR values (p ¼
.07). At 6 months, CFR and IMR were not signiﬁ-
antly different between the groups. Baseline ﬂow and
d/Pa remained stable over time but FFR reduced
igniﬁcantly between PPCI and 6 months (p ¼ 0.008);
his reduction was mainly observed in patients with
VO (p ¼ 0.006) but not in those without MVO (p ¼
.21).
ONCLUSIONS In PPCI-treated patients with STEMI,
oronary microcirculation begins to recover within 24
and recovery progresses further by 6 months. FFR
igniﬁcantly reduces from baseline to 6 months. The
resence of MVO indicates a highly dysfunctional
icrocirculation (12).T-Segment Elevation Myocardial Infarction
reated by Radial or Femoral Approach in a
ulticenter Randomized Clinical Trial:
he STEMI-RADIAL Trial
Bernat, et al.
BJECTIVES This study sought to compare radial and
moral approaches in patients presenting with ST-
egment elevation myocardial infarction (STEMI) and
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591undergoing primary percutaneous coronary intervention
(PCI) by high-volume operators experienced in both
access sites.
BACKGROUND The exact clinical beneﬁt of the radial
compared to the femoral approach remains
controversial.
METHODS STEMI-RADIAL (ST Elevation Myocardial
Infarction treated by RADIAL or femoral approach) was
a randomized, multicenter trial. A total of 707 patients
referred for STEMI <12 h of symptom onset were
randomized in 4 high-volume radial centers. The
primary endpoint was the cumulative incidence of
major bleeding and vascular access site complications
at 30 days. The rate of net adverse clinical events
(NACE) was deﬁned as a composite of death,
myocardial infarction, stroke, and major bleeding/
vascular complications. Access site crossover, contrast
volume, duration of intensive care stay, and death at
6 months were secondary endpoints.
RESULTS The primary endpoint occurred in 1.4% of
the radial group (n ¼ 348) and 7.2% of the femoral
group (n ¼ 359; p ¼ 0.0001). The NACE rate was 4.6%
versus 11.0% (p ¼ 0.0028), respectively. Crossover
from radial to femoral approach was 3.7%. Intensive
care stay (2.5  1.7 days vs. 3.0  2.9 days, p ¼ 0.0038)
as well as contrast utilization (170  71 ml vs. 182  60
ml, p ¼ 0.01) were signiﬁcantly reduced in the radial
group. Mortality in the radial and femoral groups was
2.3% versus 3.1% (p ¼ 0.64) at 30 days and 2.3% versus
3.6% (p ¼ 0.31) at 6 months, respectively.
CONCLUSIONS In patients with STEMI undergoing
primary PCI by operators experienced in both access
sites, the radial approach was associated with signiﬁ-
cantly lower incidence of major bleeding and access
site complications and superior net clinical beneﬁt.
These ﬁndings support the use of the radial approach
in primary PCI as ﬁrst choice after proper training.
(Trial Comparing Radial and Femoral Approach in
Primary Percutaneous Coronary Intervention [PCI]
[STEMI-RADIAL]; NCT01136187) (13).
Ticagrelor Effects on Myocardial Infarction and
the Impact of Event Adjudication in the PLATO
(Platelet Inhibition and Patient Outcomes) Trial
K.W. Mahaffey, et al.
OBJECTIVES This study sought to report the treat-
ment effect of ticagrelor on myocardial infarction (MI)
and the strategy for and impact of event adjudication
in the PLATO (Platelet Inhibition and Patient Out-
comes) trial.BACKGROUND In PLATO, ticagrelor reduced cardio-
vascular death, MI, or stroke in patients with acute
coronary syndromes (ACS).
METHODS A clinical events committee (CEC) pro-
spectively deﬁned and adjudicated all suspected MI
events, on the basis of events reported by in-
vestigators and by triggers on biomarkers. Treatment
comparisons used CEC-adjudicated data, and per
protocol, excluded silent MI.
RESULTS Overall, 1,299 (610 ticagrelor, 689 clopidog-
rel) MIs reported by the CEC occurred during the trial.
Of these, 1,097 (504 ticagrelor, 593 clopidogrel)
contributed to the primary composite endpoint. Site
investigators reported 1,198 (580 ticagrelor, 618 clo-
pidogrel) MIs. Ticagrelor signiﬁcantly reduced overall
MI rates (12-month CEC-adjudicated Kaplan-Meier
rates: 5.8% ticagrelor, 6.9% clopidogrel; hazard ratio
[HR]: 0.84; 95% conﬁdence interval [CI]: 0.75 to
0.95). Nonprocedural MI (HR: 0.86; 95% CI: 0.74 to
1.01) and MI related to percutaneous coronary
intervention or stent thrombosis tended to be lower
with ticagrelor. MIs related to coronary artery bypass
graft surgery were few, but numerical excess was
observed in patients assigned ticagrelor. Analyses of
overall MIs using investigator-reported data showed
similar results but did not reach statistical
signiﬁcance (HR: 0.88; 95% CI: 0.78 to 1.00).
CONCLUSIONS In patients with ACS, ticagrelor
signiﬁcantly reduced the incidence of MI compared
with clopidogrel, with consistent results across most
MI subtypes. CEC procedures identiﬁed more MI
endpoints compared with site investigators. (A Com-
parison of Ticagrelor [AZD6140] and Clopidogrel in
Patients With Acute Coronary Syndrome [PLATO];
NCT00391872) (14).
Coronary Stent Thrombosis With Vorapaxar
Versus Placebo: Results From the
TRA 2P-TIMI 50 Trial
M.P. Bonaca, et al.
BACKGROUND Vorapaxar, a novel thrombin receptor
antagonist, reduces cardiovascular death and recur-
rent thrombotic events when added to standard anti-
platelet therapy in patients with stable atherosclerotic
vascular disease.
OBJECTIVES The goal of this study was to test the
hypothesis that treatment with vorapaxar reduces the
rate of coronary stent thrombosis (ST) in stable pa-
tients with a history of coronary stenting.
METHODS TRA 2P-TIMI 50 (Trial to Assess the Effects
of Vorapaxar in Preventing Heart Attack and Stroke in
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592Patients With Atherosclerosis-Thrombolysis In
Myocardial Infarction 50) was a multinational,
randomized, double-blind, placebo-controlled trial of
vorapaxar in stable patients with prior myocardial
infarction, peripheral arterial disease, or stroke. We
evaluated the rates of deﬁnite ST as adjudicated by a
central events committee using Academic Research
Consortium (ARC) criteria.
RESULTS A total of 26,449 patients were randomized,
with 14,042 (53%) having a history of a coronary stent
implantation before randomization, and an additional
449 patients receiving a coronary stent during the trial
(total 14,491). During follow-up (median 2.5 years),
there were 152 deﬁnite ST events, with the majority
(92%) occurring late or very late. Vorapaxar reduced
ARC deﬁnite ST (1.1% vs. 1.4%, hazard ratio [HR]:
0.71, 95% conﬁdence interval [CI]: 0.51 to 0.98; p ¼
0.037). The reduction was consistent, regardless of
time from percutaneous coronary intervention,
history of diabetes, use of drug-eluting stents, and use
of dual antiplatelet therapy (DAPT) at randomization.
Vorapaxar increased GUSTO moderate/severe bleeding
(HR: 1.57, 95% CI: 1.26 to 1.94; p < 0.001).
CONCLUSIONS The rate of ARC deﬁnite ST in stable
patients, the majority of whom were receiving DAPT,
was approximately 1.4% at 3 years. In stable patients
with coronary stenting receiving standard anti-
platelet therapy, vorapaxar administered for long-
term secondary prevention signiﬁcantly reduced ARC
deﬁnite ST, including very late ST. (Trial to Assess
the Effects of Vorapaxar [SCH 530348; MK-5348]
in Preventing Heart Attack and Stroke in Patients
With Atherosclerosis [TRA 2P-TIMI 50] [P04737];
NCT00526474) (15).
Second-Generation Drug-Eluting Stent
Implantation Followed by 6- Versus 12-Month
Dual Antiplatelet Therapy: The SECURITY
Randomized Clinical Trial
A. Colombo, et al.
BACKGROUND The optimal duration of dual anti-
platelet therapy (DAPT) following second-generation
drug-eluting stent (DES) implantation is still debated.
OBJECTIVES The aim of this study was to test the
noninferiority of 6 versus 12 months of DAPT in pa-
tients undergoing percutaneous coronary intervention
with second-generation DES.
METHODS The SECURITY (Second Generation Drug-
Eluting Stent Implantation Followed by Six- Versus
Twelve-MonthDual Antiplatelet Therapy) trial was a 1:1
randomized, multicenter, international, investigator-
driven, noninferiority study conducted from July 2009to June 2014. Patients with a stable or unstable angina
diagnosis or documented silent ischemia undergoing
revascularizationwith at least 1 second-generation DES
were eligible. The primary endpoint was a composite of
cardiac death, myocardial infarction (MI), stroke,
deﬁnite or probable stent thrombosis, or Bleeding
Academic Research Consortium (BARC) type 3 or 5
bleeding at 12 months. The main secondary endpoint
was a composite of cardiac death, MI, stroke, deﬁnite
or probable stent thrombosis, or BARC type 2, 3, or 5
bleeding at 12 and 24 months.
RESULTS Overall, 1,399 patients were enrolled in the
study and randomized to receive 6 months (n ¼ 682)
versus 12 months (n ¼ 717) DAPT. The primary com-
posite endpoint occurred, respectively, in 4.5% versus
3.7% (risk difference 0.8%; 95% conﬁdence interval
[CI]: 2.4% to 1.7%; p ¼ 0.469) at 12 months. The
upper 95% CI limit was lower than the pre-set margin
of 2%, conﬁrming the noninferiority hypothesis (p <
0.05). Moreover, no differences were observed in the
occurrence of the secondary endpoint at 12 months
(5.3% vs. 4.0%, difference: 1.2%; 95% CI: 1.0 to 3.4;
p ¼ 0.273) and between 12 and 24 months (1.5% vs.
2.2%, difference: 0.7%; 95% CI: 2.1 to 0.6; p ¼
0.289). Finally, no differences were observed in
deﬁnite or probable stent thrombosis at 12 months
(0.3% vs. 0.4%; difference: 0.1%; 95% CI: 0.7 to
0.4; p ¼ 0.694) and between 12 and 24 months of
follow-up (0.1% vs. 0%; difference: 0.1%; 95%
CI: 0.1 to 0.4; p ¼ 0.305).
CONCLUSIONS In a low-risk population, the non-
inferiority hypothesis of 6 vs. 12 months DAPT
following second-generation DES implantation ap-
pears accepted for the incidence of cardiac death, MI,
stroke, deﬁnite/probable stent thrombosis, and BARC
type 3 or 5 bleeding at 12 months. (Second Generation
Drug-Eluting Stent Implantation Followed by Six-
Versus Twelve-Month Dual Antiplatelet Therapy;
NCT00944333) (16).
Stent Thrombosis in New-Generation Drug-
Eluting Stents in Patients With STEMI Undergoing
Primary PCI: A Report From SCAAR
G. Sarno, et al.
BACKGROUND Some concerns still have not been
resolved about the long-term safety of drug-eluting
stents (DES) in patients with acute STEMI.
OBJECTIVES The aim of this study was to evaluate
the stent thrombosis (ST) rate up to 3 years in patients
with ST-segment elevation myocardial infarction
(STEMI) treated by primary percutaneous coronary
intervention (PCI) with new-generation drug-eluting
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593stents (n-DES) compared with bare-metal stents (BMS)
and old-generation drug-eluting stents (o-DES)
enrolled in the SCAAR (Swedish Coronary
Angiography and Angioplasty Registry).
METHODS From January 2007 to January 2013, 34,147
patients with STEMI were treated by PCI with n-DES
(n ¼ 4,811), o-DES (n ¼ 4,271), or BMS (n ¼ 25,065). The
risks of early/late (up to 1 year) and very late deﬁnite
ST (after 1 year) were estimated.
RESULTS Cox regression landmark analysis showed a
signiﬁcantly lower risk of early/late ST in patients
treated with n-DES (hazard ratio [HR]: 0.65; 95%
conﬁdence interval [CI]: 0.43 to 0.99; p ¼ 0.04) and o-
DES (HR: 0.60; 95% CI: 0.41 to 0.89; p ¼ 0.01)
compared with the BMS group. The risk of very late ST
was similar between the n-DES and BMS groups (HR:
1.52; 95% CI: 0.78 to 2.98; p ¼ 0.21), whereas a higher
risk of very late ST was observed with o-DES compared
with BMS (HR: 2.88; 95% CI: 1.70 to 4.89; p < 0.01).
CONCLUSIONS Patients treated with n-DES have a
lower risk of early/late ST than patients treated with
BMS. The risk of very late ST is low and comparable
between n-DES and BMS up to 3 years of follow-up,
whereas o-DES treatment is associated with an
increased risk of very late ST. The current STEMI
guidelines might require an update in light of the
results of this and other recent studies (17).Clinical Outcomes With Bioabsorbable Polymer-
Versus Durable Polymer-Based Drug-Eluting
and Bare-Metal Stents: Evidence From a
Comprehensive Network Meta-Analysis
T. Palmerini, et al.
OBJECTIVES This study sought to investigate the
relative safety and efﬁcacy of bioabsorbable polymer
(BP)-based biolimus-eluting stents (BES) versus
durable-polymer (DP)-drug-eluting stents (DES) and
bare-metal stents (BMS) by means of a network
meta-analysis.
BACKGROUND Studies have suggested that BP-BES
might reduce the risk of stent thrombosis (ST) and late
adverse outcomes compared with ﬁrst-generation DES.
However, the relative safety and efﬁcacy of BP-BES
versus newer-generation DES coated with more
biocompatible DP have not been investigated in depth.
METHODS Randomized controlled trials comparing BP-
BES versus currently U.S.-approved DES or BMS were
searched through MEDLINE, EMBASE, and Cochrane
databases. Information on study design, inclusion and
exclusion criteria, sample characteristics, and clinical
outcomes was extracted.RESULTS Data from 89 trials including 85,490 patients
were analyzed. At 1-year follow-up, BP-BES were
associated with lower rates of cardiac death/myocardial
infarction (MI), MI, and target vessel revascularization
(TVR) than BMS and lower rates of TVR than fast-
release zotarolimus-eluting stents. The BP-BES had
similar rates of cardiac death/MI, MI, and TVR
compared with other second-generation DP-DES but
higher rates of 1-year ST than cobalt-chromium
everolimus-eluting stents (CoCr-EES). The BP-BES were
associated with improved late outcomes compared with
BMS and paclitaxel-eluting stents, considering the latest
follow-up data available, with nonsigniﬁcantly different
outcomes compared with other DP-DES although higher
rates of deﬁnite ST compared with CoCr-EES.
CONCLUSIONS In this large-scale network meta-
analysis, BP-BES were associated with superior
clinical outcomes compared with BMS and ﬁrst-
generation DES and similar rates of cardiac death/MI,
MI, and TVR compared with second-generation DP-
DES but higher rates of deﬁnite ST than CoCr-EES (18).
Current Status of Bioresorbable Scaffolds in the
Treatment of Coronary Artery Disease
J. Wiebe, et al.
State-of-the-art drug-eluting metal stents are the gold
standard for interventional treatment of coronary artery
disease. Although they overcome some disadvantages
and limitations of plain balloon angioplasty and bare-
metal stents, some limitations apply, most notably a
chronic local inﬂammatory reaction due to permanent
implantation of a foreign body, restriction of vascular
vasomotion due to a metal cage, and the risk of late and
very late stent thrombosis. The development of
biodegradable scaffolds is a new approach that attempts
to circumvent these drawbacks. These devices provide
short-term scaffolding of the vessel and then dissolve,
which should theoretically circumvent the side effects
of metal drug-eluting stents. Various types of these
bioresorbable scaffolds are currently under clinical
evaluation. This review discusses different concepts of
bioresorbable scaffolds with respect to material,
design, and drug elution and presents the most recent
evidence (19).
Long-Term Outcome of PCI Versus CABG in
Insulin and Non–Insulin-Treated Diabetic
Patients: Results From the FREEDOM Trial
G.D. Dangas, et al.
BACKGROUND The prospective, randomized FREEDOM
(Comparison of Two Treatments for Multivessel Coronary
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594Artery Disease in Individuals With Diabetes) trial found
coronary artery bypass graft surgery (CABG) was associ-
ated with better clinical outcomes than percutaneous
coronary intervention (PCI) in patients with diabetes
and multivessel disease, managed with or without
insulin.
OBJECTIVES In this subgroup analysis of the
FREEDOM trial, we examined the association of long-
term clinical outcomes after revascularization in
patients with insulin-treated diabetes mellitus (ITDM)
compared with patients not treated with insulin.
METHODS A total of 1,850 FREEDOM subjects had an
index revascularization procedure performed: 956 un-
derwent PCI with drug-eluting stents (DES), and 894
underwent CABG. A total of 602 patients (32.5%) had
ITDM (PCI/DES n ¼ 325, 34%; CABG n ¼ 277, 31%).
Subjects were classiﬁed according to ITDM versus non-
ITDM, with comparison of PCI/DES versus CABG for
each group. Interaction analyses were performed for
treatment by diabetes mellitus (DM) status alone and
for treatment by DM status by coronary lesion
complexity. Analyses were performed for the primary
outcome composite of death/stroke/myocardial
infarction (MI) using all available follow-up data.
RESULTS The overall 5-year event rate of death/stroke/
MI was signiﬁcantly higher in ITDM versus non-ITDM
patients (28.7% vs. 19.5%, p < 0.001), which persisted
even after adjustment for multiple baseline factors,
angiographic complexity, and revascularization
treatment group (death/stroke/MI hazard ratio [HR]:
1.35, 95% conﬁdence interval [CI]: 1.06 to 1.73, p ¼
0.014). With respect to the primary composite
endpoint, CABG was superior to PCI/DES in both DM
types and the magnitude of treatment effect was
similar (interaction p ¼ 0.40) for ITDM (PCI vs. CABG
HR: 1.21; 95% CI: 0.87 to 1.69) and non-ITDM patients
(PCI vs. CABG HR: 1.46; 95% CI 1.10 to 1.94), even after
adjusting for the angiographic SYNTAX score level.
Based on 5-year event rates, the number needed to
treat with CABG versus PCI to prevent 1 event is 12.7 in
ITDM and 13.2 in non-ITDM.
CONCLUSIONS In patients with diabetes and multi-
vessel coronary artery disease, the rate of major
adverse cardiovascular events (death, MI, or stroke) is
higher in patients treated with insulin than in those
not treated with insulin. Furthermore, we did not
detect a signiﬁcant difference in the magnitude of PCI
versus CABG treatment effect for patients treated with
insulin and those not treated with insulin. (Compari-
son of Two Treatments for Multivessel Coronary Ar-
tery Disease in Individuals With Diabetes [FREEDOM];
NCT00086450) (20).Long-Term Survival Following Coronary Artery
Bypass Grafting: Off-Pump Versus On-Pump
Strategies
J.B. Kim, et al.
OBJECTIVES This study sought to compare long-term
survival after off- and on-pump coronary artery
bypass grafting (CABG).
BACKGROUND Although several large-scale clinical
trials have compared the surgical outcomes between
off- and on-pump CABG, the long-term survival has
not been compared between the 2 surgical strategies
in a reasonably sized cohort.
METHODS Weevaluated long-termsurvival data in 5,203
patients (age 62.9  9.1 years, 1,340 females) who
underwent elective isolated CABG (off-pump: n ¼ 2,333;
on-pump: n ¼ 2,870) from 1989 through 2012. Vital
statuses were validated using the Korean National
Registry of Vital Statistics. Long-term survival was
compared with the use of propensity scores and inverse
probability weighting to adjust selection bias.
RESULTS Patients undergoing on-pump CABG had a
higher number of distal anastomoses than those
undergoing off-pump CABG (3.7  1.2 vs. 3.0  1.1;
p < 0.001). Survival data were complete in 5,167 patients
(99.3%), with a median follow-up duration of 6.4 years
(interquartile range: 3.7 to 10.5 years; maximum 23.1
years). During follow-up, 1,181 patients (22.7%) died.
After adjustment, both groups of patients showed a
similar risk of death at 30 days (odds ratio: 0.70; 95%
conﬁdence interval [CI]: 0.35 to 1.40; p ¼ 0.31) and up to
1 year (hazard ratio [HR]: 1.11; 95% CI: 0.74 to 1.65;
p ¼ 0.62). For overall mortality, however, patients
undergoing off-pump CABG were at a signiﬁcantly
higher risk of death (HR: 1.43; 95% CI: 1.19 to 1.71; p <
0.0001) compared with those undergoing on-pump
CABG. In subgroup analyses, on-pump CABG conferred
survival beneﬁts in most demographic, clinical, and
anatomic subgroups compared with off-pump CABG.
CONCLUSIONS In patients undergoing elective isolated
CABG, on-pump strategy conferred a long-term survival
advantage compared with off-pump strategy (21).
Drug-Eluting Balloon Versus Standard Balloon
Angioplasty for Infrapopliteal Arterial
Revascularization in Critical Limb Ischemia:
12-Month Results From the IN.PACT DEEP
Randomized Trial
T. Zeller, et al.
BACKGROUND Drug-eluting balloons (DEB) may
reduce infrapopliteal restenosis and reintervention
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595rates versus percutaneous transluminal angioplasty
(PTA) and improve wound healing/limb preservation.
OBJECTIVES The goal of this clinical trial was to
assess the efﬁcacy and safety of IN.PACT Amphirion
drug-eluting balloons (IA-DEB) compared to PTA for
infrapopliteal arterial revascularization in patients
with critical limb ischemia (CLI).
METHODS Within a prospective, multicenter, ran-
domized, controlled trial with independent clinical
event adjudication and angiographic and wound core
laboratories 358 CLI patients were randomized 2:1 to
IA-DEB or PTA. The 2 coprimary efﬁcacy endpoints
through 12 months were clinically driven target
lesion revascularization (CD-TLR) and late lumen
loss (LLL). The primary safety endpoint through
6 months was a composite of all-cause mortality,
major amputation, and CD-TLR.
RESULTS Clinical characteristics were similar be-
tween the 2 groups. Signiﬁcant baseline differences
between the IA-DEB and PTA arms included mean
lesion length (10.2 cm vs. 12.9 cm; p ¼ 0.002),
impaired inﬂow (40.7% vs. 28.8%; p ¼ 0.035), and
previous target limb revascularization (32.2% vs.
21.8%; p ¼ 0.047). Primary efﬁcacy results of IA-DEB
versus PTA were CD-TLR of 9.2% versus 13.1% (p ¼
0.291) and LLL of 0.61  0.78 mm versus 0.62  0.78
mm (p ¼ 0.950). Primary safety endpoints were
17.7% versus 15.8% (p ¼ 0.021) and met the
noninferiority hypothesis. A safety signal driven by
major amputations through 12 months was observed
in the IA-DEB arm versus the PTA arm (8.8% vs.
3.6%; p ¼ 0.080).
CONCLUSIONS In patients with CLI, IA-DEB had
comparable efﬁcacy to PTA. While primary safety
was met, there was a trend towards an increased
major amputation rate through 12 months compared
to PTA. (Study of IN.PACT Amphirion Drug Eluting
Balloon vs. Standard PTA for the Treatment of Below
the Knee Critical Limb Ischemia [INPACT-DEEP];
NCT00941733) (22).Effect of Atorvastatin Therapy on Fibrous Cap
Thickness in Coronary Atherosclerotic Plaque as
Assessed by Optical Coherence Tomography:
The EASY-FIT Study
K. Komukai, et al.
BACKGROUND The detailed mechanism of plaque
stabilization by statin therapy is not fully understood.
OBJECTIVES The aim of this study was to assess the
effect of lipid-lowering therapy with 20 mg/day ofatorvastatin versus 5 mg/day of atorvastatin on
ﬁbrous cap thickness in coronary atherosclerotic
plaques by using optical coherence tomography (OCT).
METHODS Seventy patients with unstable angina
pectoris and untreated dyslipidemia were random-
ized to either 20 mg/day or 5 mg/day of atorvastatin
therapy. OCT was performed to assess intermediate
nonculprit lesions at baseline and 12-month
follow-up.
RESULTS Serum low-density lipoprotein cholesterol
level was signiﬁcantly lower during therapy with 20
mg/day compared with 5 mg/day of atorvastatin (69
mg/dl vs. 78 mg/dl; p ¼ 0.039). The increase in ﬁbrous
cap thickness was signiﬁcantly greater with 20 mg/
day compared with 5 mg/day of atorvastatin (69% vs.
17%; p < 0.001). The increase in ﬁbrous cap thickness
correlated with the decrease in serum levels of
low-density lipoprotein cholesterol (R ¼ 0.450;
p < 0.001), malondialdehyde-modiﬁed low-density
lipoprotein (R ¼ 0.283; p ¼ 0.029), high-sensitivity
C-reactive protein (R ¼ 0.276; p ¼ 0.033), and matrix
metalloproteinase-9 (R ¼ 0.502; p < 0.001), and the
decrease in grade of OCT-derived macrophages
(R ¼ 0.415; p ¼ 0.003).
CONCLUSIONS Atorvastatin therapy at 20 mg/day
provided a greater increase in ﬁbrous cap thickness in
coronary plaques compared with 5 mg/day of atorvas-
tatin. The increase of ﬁbrous cap was associated with
the decrease in serum atherogenic lipoproteins and
inﬂammatory biomarkers during atorvastatin therapy.
(Effect of Atorvastatin Therapy on Fibrous Cap Thick-
ness in Coronary Atherosclerotic Plaque as Assessed by
Optical Coherence Tomography: The EASY-FIT Study;
NCT00700037) (23).GENETICS, OMICS, & TISSUE REGENERATION
Targeted Next-Generation Sequencing Identiﬁes
Pathogenic Variants in Familial Congenital Heart
Disease
G.M. Blue, et al.
BACKGROUND Many genes have been implicated in
the development of congenital heart disease (CHD).
Next-generation sequencing offers opportunities for
genetic testing but is often complicated by logistic
and interpretative hurdles.
OBJECTIVES This study sought to apply next-
generation sequencing technology to CHD families
with multiple affected members using a purpose-
designed gene panel to assess diagnostic potential
for future clinical applications.
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sequencing gene panel for 57 genes previously
implicated in CHD. Probands were screened in 16
families with strong CHD histories and in 15 control
subjects. Variants affecting protein-coding regions
were classiﬁed in silico using prediction programs and
ﬁltered according to predicted mode of inheritance,
minor allele frequencies, and presence in databases
such as dbSNP (Single Nucleotide Polymorphism
Database) and ESP (Exome Sequencing Project).
Disease segregation studies were conducted in
variants identiﬁed in CHD cases predicted to be
deleterious and with minor allele frequencies <0.1%.
RESULTS Thirteen potential disease-causing variants
were identiﬁed in 9 families. Of these, 5 variants
segregated with disease phenotype, revealing a likely
molecular diagnosis in 31% of this cohort. Signiﬁcant
increases in the number of “indels, nonsense, and
splice” variants, as well as variants classiﬁed as
“probably damaging” were identiﬁed in CHD cases but
not in control subjects. Also, there was a signiﬁcant
increase in the total number of “rare” and “low”
frequency variants (minor allele frequencies <0.05) in
the CHD cases.
CONCLUSIONS When multiple relatives are affected
by CHD, a gene panel–based approach may identify its
cause in up to 31% of families. Identifying causal
variants has implications for clinical care and future
family planning (24).
A Roadmap to Investigate the Genetic Basis of
Bicuspid Aortic Valve and its Complications:
Insights From the International BAVCon
(Bicuspid Aortic Valve Consortium)
S.K. Prakash, et al.
Bicuspid aortic valve (BAV) is the most common adult
congenital heart defect and is found in 0.5% to 2.0%
of the general population. The term “BAV” refers to a
heterogeneous group of disorders characterized
by diverse aortic valve malformations with associated
aortopathy, congenital heart defects, and genetic
syndromes. Even after decades of investigation, the
genetic determinants of BAV and its complications
remain largely undeﬁned. Just as BAV phenotypes are
highly variable, the genetic etiologies of BAV are
equally diverse and vary from complex inheritance
in families to sporadic cases without any evidence
of inheritance. In this paper, the authors discuss
current concepts in BAV genetics and propose a
roadmap for unraveling unanswered questions about
BAV through the integrated analysis of genetic and
clinical data (25).Yield of Serial Evaluation in At-Risk Family
Members of Patients With ARVD/C
A.S.J.M. te Riele, et al.
BACKGROUND Incomplete penetrance and variable
expressivity of arrhythmogenic right ventricular
dysplasia/cardiomyopathy (ARVD/C) complicate fam-
ily screening.
OBJECTIVES The objective of the present study was
to determine the optimal approach to longitudinal
follow-up regarding: 1) screening interval; and 2)
testing strategy in at-risk relatives of ARVD/C patients.
METHODS We included 117 relatives (45%male, age 33.3
 16.3 years) from 64 families who were at risk of
developing ARVD/C by virtue of their familial predispo-
sition (72% mutation carriers [92% plakophilin-2]; 28%
ﬁrst-degree relatives of a mutation-negative proband).
Subjects were evaluated by electrocardiography (ECG),
Holter monitoring, signal-averaged ECG, and cardiac
magnetic resonance (CMR). Disease progression was
deﬁned as the development of a new criterion by the
2010 Task Force Criteria (not the “Hamid criteria”) at
last follow-up that was absent at enrollment.
RESULTS At ﬁrst evaluation, 43 subjects (37%) ful-
ﬁlled an ARVD/C diagnosis according to the 2010
Task Force Criteria. Among the remaining 74 sub-
jects (63%), 11 of 37 (30%) with complete re-
evaluation experienced disease progression during
4.1  2.3 years of follow-up. Electrical progression
(n ¼ 10 [27%], including by ECG [14%], Holter
monitoring [11%], or signal-averaged ECG [14%])
was more frequently observed than structural
progression (n ¼ 1 [3%] on CMR). All 5 patients
(14%) with clinical ARVD/C diagnosis at last follow-
up had an abnormal ECG or Holter monitor
recording, and the only patient with an abnormal
CMR already had an abnormal ECG at enrollment.
CONCLUSIONS Over a mean follow-up of 4 years, our
study showed that: 1) almost one-third of at-risk
relatives have electrical progression; 2) structural
progression is rare; and 3) electrical abnormalities
precede detectable structural changes. This information
could be valuable in determining family screening
protocols (26).Mutations in SCN10A Are Responsible for a
Large Fraction of Cases of Brugada Syndrome
D. Hu, et al.
BACKGROUND BrS is an inherited sudden cardiac
death syndrome. Less than 35% of BrS probands have
genetically identiﬁed pathogenic variants. Recent
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597evidence has implicated SCN10A, a neuronal sodium
channel gene encoding Nav1.8, in the electrical func-
tion of the heart.
OBJECTIVES The purpose of this study was to test the
hypothesis that SCN10A variants contribute to the
development of Brugada syndrome (BrS).
METHODS Clinical analysis and direct sequencing of
BrS susceptibility genes were performed for 150 pro-
bands and family members as well as >200 healthy
controls. Expression and coimmunoprecipitation
studies were performed to functionally characterize
the putative pathogenic mutations.
RESULTS We identiﬁed 17 SCN10A mutations in 25
probands (20 male and 5 female); 23 of the 25 probands
(92.0%) displayed overlapping phenotypes. SCN10A
mutations were found in 16.7% of BrS probands,
approaching our yield for SCN5A mutations (20.1%).
Patients with BrS who had SCN10A mutations were
more symptomatic and displayed signiﬁcantly longer PR
and QRS intervals compared with SCN10A-negative BrS
probands. The majority of mutations localized to
the transmembrane-spanning regions. Heterologous
coexpression of wild-type (WT) SCN10A with WT-
SCN5A in HEK cells caused a near doubling of sodium
channel current compared with WT-SCN5A alone. In
contrast, coexpression of SCN10A mutants (R14L and
R1268Q) with WT-SCN5A caused a 79.4% and 84.4%
reduction in sodium channel current, respectively. The
coimmunoprecipitation studies provided evidence for
the coassociation of Nav1.8 and Nav1.5 in the plasma
membrane.
CONCLUSIONS Our study identiﬁed SCN10A as a ma-
jor susceptibility gene for BrS, thus greatly enhancing
our ability to genotype and risk stratify probands and
family members (27).
HCN4 Mutations in Multiple Families With
Bradycardia and Left Ventricular Noncompaction
Cardiomyopathy
A. Milano, et al.
BACKGROUND Familial forms of primary sinus
bradycardia have sometimes been attributed to mu-
tations in HCN4, SCN5A, and ANK2. In these studies,
no structural cardiac alterations were reported in
mutation carriers. However, a cluster of reports in the
literature describe patients presenting with sinus
bradycardia in association with left ventricular non-
compaction cardiomyopathy (LVNC), pointing to a
shared genetic cause.
OBJECTIVES This study sought to identify the genetic
defect underlying the combined clinical presentationof bradycardia and LVNC, hypothesizing that these 2
clinical abnormalities have a common genetic cause.
METHODS Exome sequencing was carried out in 2
cousins from the index family that were affected by
the combined bradycardia–LVNC phenotype; shared
variants thus identiﬁed were subsequently overlaid
with the chromosomal regions shared among 5
affected family members that were identiﬁed using
single nucleotide polymorphism array analysis.
RESULTS The combined linkage analysis and exome
sequencing in the index family identiﬁed 11 novel
variants shared among the 2 affected cousins. One of
these, p.Gly482Arg in HCN4, segregated with the
combined bradycardia and LVNC phenotype in the
entire family. Subsequent screening of HCN4 in 3
additional families with the same clinical combination
of bradycardia and LVNC identiﬁed HCN4 mutations
in each. In electrophysiological studies, all found
HCN4 mutations showed a more negative voltage
dependence of activation, consistent with the
observed bradycardia.
CONCLUSIONS Although mutations in HCN4 have
been previously linked to bradycardia, our study
provides the ﬁrst evidence to our knowledge that
mutations in this ion channel gene also may be asso-
ciated with structural abnormalities of the myocar-
dium (28).
microRNAs in Cardiovascular Diseases:
Current Knowledge and the Road Ahead
G. Condorelli, et al.
Over the last few years, the ﬁeld of microribonucleic
acid (miRNA) in cardiovascular biology and disease
has expanded at an incredible pace. miRNAs are
themselves part of a larger family, that of non-coding
RNAs, the importance of which for biological processes
is starting to emerge. miRNAs are w22-nucleotide-long
RNA sequences that can legate messenger (m)RNAs at
partially complementary binding sites, and hence
regulate the rate of protein synthesis by altering the
stability of the targeted mRNAs. In the cardiovascular
system, miRNAs have been shown to be critical
regulators of development and physiology. They
control basic functions in virtually all cell types
relevant to the cardiovascular system (such as
endothelial cells, cardiac muscle, smooth muscle,
inﬂammatory cells, and ﬁbroblasts) and, thus, are
directly involved in the pathophysiology of many
cardiovascular diseases. As a result of their role in
disease, they are being studied for exploitation in
diagnostics, prognostics, and therapeutics. However,
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overcome before they enter the clinical arena. We
present here a review of the literature and outline the
directions toward their use in the clinic (29).
Circulating miR-29a, Among Other Up-Regulated
MicroRNAs, Is the Only Biomarker for Both
Hypertrophy and Fibrosis in Patients With
Hypertrophic Cardiomyopathy
R. Roncarati, et al.
OBJECTIVES The purpose of this paper was to deter-
mine whether microRNAs (miRNAs) involved in
myocardial remodeling were differentially expressed
in the blood of hypertrophic cardiomyopathy (HCM)
patients, and whether circulating miRNAs correlated
with the degree of left ventricular hypertrophy and
ﬁbrosis.
BACKGROUND miRNAs—small, noncoding ribonucleic
acids (RNAs) that regulate gene expression by inhibit-
ing RNA translation—modulate cellular function.
Myocardial miRNAs modulate processes such as car-
diomyocyte (CM) hypertrophy, excitation–contraction
coupling, and apoptosis; non–CM-speciﬁc miRNAs
regulate myocardial vascularization and ﬁbrosis.
Recently, the possibility that circulating miRNAs may
be biomarkers of cardiovascular disease has been
raised.
METHODS Forty-one HCM patients were character-
ized with conventional transthoracic echocardiogra-
phy and cardiac magnetic resonance. Peripheral
plasma levels of 21 miRNAs were assessed by quanti-
tative real-time polymerase chain reaction and were
compared with levels in a control group of 41 age-
and sex-matched blood donors.
RESULTS Twelve miRNAs (miR-27a, -199a-5p, -26a,
-145, -133a, -143, -199a-3p, -126-3p, -29a, -155, -30a,
and -21) were signiﬁcantly increased in HCM plasma.
However, only 3 miRNAs (miR-199a-5p, -27a, and -29a)
correlated with hypertrophy; more importantly, only
miR-29a correlated also with ﬁbrosis.
CONCLUSIONS Our data suggest that cardiac remod-
eling associated with HCM determines a signiﬁcant
release of miRNAs into the bloodstream: the circu-
lating levels of both cardiac- and non–cardiac-speciﬁc
miRNAs are signiﬁcantly increased in the plasma of
HCM patients. However, correlation with left ven-
tricular hypertrophy parameters holds true for only a
few miRNAs (i.e, miR-199a-5p, -27a, and -29a),
whereas only miR-29a is signiﬁcantly associated with
both hypertrophy and ﬁbrosis, identifying it as a
potential biomarker for myocardial remodeling
assessment in HCM (30).Novel Genetic Markers Associate With Atrial
Fibrillation Risk in Europeans and Japanese
S.A. Lubitz, et al.
OBJECTIVES This study sought to identify nonredun-
dant atrial ﬁbrillation (AF) genetic susceptibility signals
and examine their cumulative relations with AF risk.
BACKGROUND AF-associated loci span broad genomic
regions that may contain multiple susceptibility sig-
nals. Whether multiple signals exist at AF loci has not
been systematically explored.
METHODS We performed association testing condi-
tioned on the most signiﬁcant, independently associ-
ated genetic markers at 9 established AF loci using 2
complementary techniques in 64,683 individuals of
European ancestry (3,869 incident and 3,302 prevalent
AF cases). Genetic risk scores were created and tested
for association with AF in Europeans and an inde-
pendent sample of 11,309 individuals of Japanese
ancestry (7,916 prevalent AF cases).
RESULTS We observed at least 4 distinct AF suscep-
tibility signals on chromosome 4q25 upstream of
PITX2, but not at the remaining 8 AF loci. A multilocus
score comprised 12 genetic markers demonstrated an
estimated 5-fold gradient in AF risk. We observed a
similar spectrum of risk associated with these
markers in Japanese. Regions containing AF signals
on chromosome 4q25 displayed a greater degree of
evolutionary conservation than the remainder of the
locus, suggesting that they may tag regulatory
elements.
CONCLUSIONS The chromosome 4q25 AF locus is
architecturally complex and harbors at least 4 AF sus-
ceptibility signals in individuals of European ancestry.
Similar polygenic AF susceptibility exists between Eu-
ropeans and Japanese. Future work is necessary to
identify causal variants, determine mechanisms by
which associated loci predispose to AF, and explore
whether AF susceptibility signals classify individuals at
risk for AF and related morbidity (31).
Induced Pluripotent Stem Cells for the Study of
Cardiovascular Disease
J.J. Savla, et al.
Groundbreaking advances in stem cell research have
led to techniques for the creation of human
cardiomyocytes from cells procured from a variety of
sources, including a simple skin biopsy. Since the
advent of this technology, most research has focused
on utilizing these cells for therapeutic purposes.
However, recent studies have demonstrated that stem
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with inherited cardiovascular disorders recapitulate
key phenotypic features of disease in vitro.
Furthermore, these cells can be maintained in culture
for prolonged periods of time and used for extensive
biochemical and physiological analysis. By serving as
models of inherited cardiac disorders, these systems
have the potential to fundamentally change the
manner in which cardiovascular disease is studied
and new therapies are developed (32).
Intracoronary Cardiosphere-Derived Cells After
Myocardial Infarction: Evidence of Therapeutic
Regeneration in the Final 1-Year Results of the
CADUCEUS Trial (CArdiosphere-Derived
aUtologous stem CElls to reverse ventricUlar
dySfunction)
K. Malliaras, et al.
OBJECTIVES This study sought to report full 1-year
results, detailed magnetic resonance imaging analysis,
and determinants of efﬁcacy in the prospective,
randomized, controlled CADUCEUS (CArdiosphere-
Derived aUtologous stem CElls to reverse ventricUlar
dySfunction) trial.
BACKGROUND Cardiosphere-derived cells (CDCs)
exerted regenerative effects at 6 months in the
CADUCEUS trial. Complete results at the ﬁnal 1-year
endpoint are unknown.
METHODS Autologous CDCs (12.5 to 25  106) grown
from endomyocardial biopsy specimens were infused
via the intracoronary route in 17 patients with left
ventricular dysfunction 1.5 to 3 months after myocar-
dial infarction (MI) (plus 1 infused off-protocol 14
months post-MI). Eight patients were followed as
routine-care control patients.
RESULTS In 13.4 months of follow-up, safety endpoints
were equivalent between groups. At 1 year, magnetic
resonance imaging revealed that CDC-treated patients
had smaller scar size compared with control patients.
Scar mass decreased and viable mass increased in
CDC-treated patients but not in control patients. The
single patient infused 14 months post-MI responded
similarly. CDC therapy led to improved regional
function of infarcted segments compared with control
patients. Scar shrinkage correlated with an increase in
viability and with improvement in regional function.
Scar reduction correlated with baseline scar size but
not with a history of temporally remote MI or time
from MI to infusion. The changes in left ventricular
ejection fraction in CDC-treated subjects were
consistent with the natural relationship between scar
size and ejection fraction post-MI.CONCLUSIONS Intracoronary administration of autol-
ogous CDCs did not raise signiﬁcant safety concerns.
Preliminary indications of bioactivity include decreased
scar size, increased viable myocardium, and improved
regional function of infarcted myocardium at 1 year
post-treatment. These results, which are consistent with
therapeutic regeneration, merit further investigation in
future trials. (CArdiosphere-Derived aUtologous stem
CElls to reverse ventricUlar dySfunction [CADUCEUS];
NCT00893360) (33).Cultured Human Bone Marrow–Derived CD31þ
Cells Are Effective for Cardiac and Vascular
Repair Through Enhanced Angiogenic, Adhesion,
and Anti-Inﬂammatory Effects
S.-W. Kim, et al.
BACKGROUND Cell therapy for cardiovascular dis-
ease has been limited by low engraftment of
administered cells and modest therapeutic effects.
Bone marrow (BM) -derived CD31þ cells are a
promising cell source owing to their high angio-
vasculogenic and paracrine activities.
OBJECTIVES This study sought to identify culture
conditions that could augment the cell adhesion,
angiogenic, and anti-inﬂammatory activities of BM-
derived CD31þ cells, and to determine whether these
cultured CD31þ cells are effective for cardiac and
vascular repair.
METHODS CD31þ cells were isolated from human BM
by magnetic-activated cell sorting and cultured for 10
days under hematopoietic stem cell, mesenchymal
stem cell, or endothelial cell culture conditions. These
cells were characterized by adhesion, angiogenesis,
and inﬂammatory assays. The best of the cultured
cells were implanted into myocardial infarction (MI)
and hindlimb ischemia (HLI) models to determine
therapeutic effects and underlying mechanisms.
RESULTS The CD31þ cells cultured in endothelial cell
medium (EC-CD31þ cells) showed the highest adhe-
sion and angiogenic activities and lowest inﬂamma-
tory properties in vitro compared with uncultured or
other cultured CD31þ cells. When implanted into
mouse MI or HLI models, EC-CD31þ cells improved
cardiac function and repaired limb ischemia to a
greater extent than uncultured CD31þ cells. Histolog-
ically, injected EC-CD31þ cells exhibited higher
retention, neovascularization, and cardiomyocyte
proliferation. Importantly, cell retention and endo-
thelial transdifferentiation was sustained up to 1 year.
CONCLUSIONS Short-term cultured EC-CD31þ cells
have higher cell engraftment, vessel-formation,
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potential, are highly effective for both cardiac and
peripheral vascular repair, and enhance survival of
mice with heart failure. These cultured CD31þ cells
may be a promising source for treating ischemic
cardiovascular diseases (34).
Translating Stem Cell Research to Cardiac
Disease Therapies: Pitfalls and Prospects for
Improvement
M.R. Rosen, et al.
Over the past 2 decades, there have been numerous
stem cell studies focused on cardiac diseases, ranging
from proof-of-concept to phase 2 trials. This series of
papers focuses on the legacy of these studies and the
outlook for future treatment of cardiac diseases with
stem cell therapies. The ﬁrst section by Drs. Rosen
and Myerburg is an independent review that analyzes
the basic science and translational strategies
supporting the rapid advance of stem cell technology
to the clinic, the philosophies behind them, trial
designs, and means for going forward that may
impact favorably on progress. The second and third
sections were collected as responses to the initial
section of this review. The commentary by Drs.
Francis and Cole discusses the review by Drs. Rosen
and Myerburg and details how trial outcomes can be
affected by noise, poor trial design (particularly the
absence of blinding), and normal human tendencies
toward optimism and denial. The ﬁnal, independent
paper by Dr. Marbán takes a different perspective
concerning the potential for positive impact of stem
cell research applied to heart disease and future
prospects for its clinical application. (Compiled by the
JACC editors) (35).
Effect of Human Donor Cell Source on
Differentiation and Function of Cardiac Induced
Pluripotent Stem Cells
V. Sanchez-Freire, et al.
BACKGROUND Human-induced pluripotent stem
cells (iPSCs) are a potentially unlimited source for
generation of cardiomyocytes (iPSC-CMs). However,
current protocols for iPSC-CM derivation face
several challenges, including variability in somatic
cell sources and inconsistencies in cardiac
differentiation efﬁciency.
OBJECTIVES This study aimed to assess the effect of
epigenetic memory on differentiation and function of
iPSC-CMs generated from somatic cell sources of
cardiac versus noncardiac origins.METHODS Cardiac progenitor cells (CPCs) and skin
ﬁbroblasts from the same donors were reprogrammed
into iPSCs and differentiated into iPSC-CMs via
embryoid body and monolayer-based differentiation
protocols.
RESULTS Differentiation efﬁciency was found to be
higher in CPC-derived iPSC-CMs (CPC-iPSC-CMs) than
in ﬁbroblast-derived iPSC-CMs (Fib-iPSC-CMs). Gene
expression analysis during cardiac differentiation
demonstrated up-regulation of cardiac transcription
factors in CPC-iPSC-CMs, including NKX2-5, MESP1,
ISL1, HAND2, MYOCD, MEF2C, and GATA4. Epigenetic
assessment revealed higher methylation in the pro-
moter region of NKX2-5 in Fib-iPSC-CMs compared
with CPC-iPSC-CMs. Epigenetic differences were
found to dissipate with increased cell passaging, and a
battery of in vitro assays revealed no signiﬁcant dif-
ferences in their morphological and electrophysiolog-
ical properties at early passage. Finally, cell delivery
into a small animal myocardial infarction model indi-
cated that CPC-iPSC-CMs and Fib-iPSC-CMs possess
comparable therapeutic capabilities in improving
functional recovery in vivo.
CONCLUSIONS This is the ﬁrst study to compare dif-
ferentiation of iPSC-CMs from human CPCs versus hu-
man ﬁbroblasts from the same donors. The authors
demonstrate that although epigenetic memory im-
proves differentiation efﬁciency of cardiac versus
noncardiac somatic cell sources in vitro, it does not
contribute to improved functional outcome in vivo (36).The Role of Monocytes in Angiogenesis and
Atherosclerosis
A.S. Jaipersad, et al.
New vessel formation inside the arterial wall and
atherosclerotic plaques plays a critical role in
pathogenesis of heart attacks and strokes. The 2 known
mechanisms resulting in the formation of new vessels
within the plaque are local ischemia and inﬂammation.
Blood monocytes play an important role in both
processes. First, they express receptors for vascular
endothelial growth factor and some of them may serve
as circulating ancestors of endothelial cells. Second,
monocytes are associated with inﬂammation by
synthesis of inﬂammatory molecules following
their activation (e.g., after stimulation of Toll-like
receptors). Neovascularization is a reparative response
to ischemia, and includes 3 processes: angiogenesis,
arteriogenesis, and vasculogenesis. Angiogenesis, the
formation of new capillary vessels is known to occur in
response to a hypoxic environment. The interaction
J A C C V O L . 6 5 , N O . 6 , 2 0 1 5 Fuster
F E B R U A R Y 1 7 , 2 0 1 5 : 5 8 6 – 6 1 4 Highlights of the Year
601between leukocytes and vascular wall via over-
expression of various molecules facilitates the
migration of inﬂammatory cells into the plaque
microenvironment. Monocytes are intimately involved
in tissue damage and repair and an imbalance of
these processes may have detrimental consequences
for plaque development and stability. Importantly,
monocytes are comprised of distinct subsets with
different cell surface markers and functional
characteristics and this heterogeneity may be relevant
to angiogenic processes in atherosclerosis. The aim of
this review article is to present an overview of the
available evidence supporting a role for monocytes in
angiogenesis and atherosclerosis (37).CV PREVENTION & HEALTH PROMOTION
Sports and Exercise Cardiology in the United States:
Cardiovascular Specialists as Members of the
Athlete Healthcare Team
C.E. Lawless, et al.
In recent years, athletic participation has more than
doubled in all major demographic groups, while
simultaneously, children and adults with established
heart disease desire participation in sports and
exercise. Despite conferring favorable long-term
effects on well-being and survival, exercise can be
associated with risk of adverse events in the short term.
Complex individual cardiovascular (CV) demands and
adaptations imposed by exercise present distinct
challenges to the cardiologist asked to evaluate athletes.
Here, we describe the evolution of sports and exercise
cardiology as a unique discipline within the continuum
of CV specialties, provide the rationale for tailoring of
CV care to athletes and exercising individuals, deﬁne
the role of the CV specialist within the athlete care
team, and lay the foundation for the development of
Sports and Exercise Cardiology in the United States. In
2011, the American College of Cardiology launched the
Section of Sports and Exercise Cardiology. Membership
has grown from 150 to over 4,000 members in just 2
short years, indicating marked interest from the CV
community to advance the integration of sports and
exercise cardiology into mainstream CV care. Although
the current athlete CV care model has distinct
limitations, here, we have outlined a new paradigm of
care for the American athlete and exercising individual.
By practicing and promoting this new paradigm, we
believe we will enhance the CV care of athletes of all
ages, and serve the greater athletic community and our
nation as a whole, by allowing safest participation in
sports and physical activity for all individuals who seek
this lifestyle (38).
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pLeisure-Time Running Reduces All-Cause and
Cardiovascular Mortality Risk
D.-C. Lee, et al.
BACKGROUND Although running is a popular leisure-
time physical activity, little is known about the
long-term effects of running on mortality. The dose-
response relations between running, as well as
the change in running behaviors over time, and
mortality remain uncertain.
OBJECTIVES We examined the associations of
running with all-cause and cardiovascular mortality
risks in 55,137 adults, 18 to 100 years of age (mean
age 44 years).
ETHODS Running was assessed on a medical history
uestionnaire by leisure-time activity.
ESULTS During a mean follow-up of 15 years, 3,413 all-
ause and 1,217 cardiovascular deaths occurred.
pproximately 24% of adults participated in running in
is population. Compared with nonrunners, runners
ad 30% and 45% lower adjusted risks of all-cause and
ardiovascular mortality, respectively, with a 3-year life
xpectancy beneﬁt. In dose-response analyses, the
ortality beneﬁts in runners were similar across
uintiles of running time, distance, frequency, amount,
nd speed, compared with nonrunners. Weekly running
ven <51 min, <6 miles, 1 to 2 times, <506 metabolic
quivalent-minutes, or <6 miles/h was sufﬁcient to
educe risk of mortality, compared with not running. In
e analyses of change in running behaviors and
ortality, persistent runners had the most signiﬁcant
eneﬁts, with 29% and 50% lower risks of all-cause and
ardiovascular mortality, respectively, compared with
ever-runners.
ONCLUSIONS Running, even 5 to 10 min/day and at
low speeds <6 miles/h, is associated with markedly
educed risks of death from all causes and cardio-
ascular disease. This study may motivate healthy
ut sedentary individuals to begin and continue
unning for substantial and attainable mortality
eneﬁts (39).
Systematic Examination of the 2013 ACC/AHA
ooled Cohort Risk Assessment Tool for
therosclerotic Cardiovascular Disease
.N. Karmali, et al.
ACKGROUND The 2013 American College of Cardi-
logy/American Heart Association updated cholesterol
uidelines recommend the use of Pooled Cohort
quations to estimate 10-year absolute risk for
therosclerotic cardiovascular disease (ASCVD) in
rimary prevention.
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602OBJECTIVES This study sought to systematically
examine the Pooled Cohort Equations to determine
risk factor levels required to exceed risk thresholds
outlined in new cholesterol guidelines.
METHODS We entered continuous risk factor levels in
isolation and in speciﬁed combinations with the risk
tool, and we observed predicted risk output patterns.
We used the 10-year ASCVD risk threshold of $7.5% as
a clinically relevant risk threshold.
RESULTS We demonstrated that a hypothetical man
or woman can reach clinically relevant risk thresholds
throughout the eligible age spectrum of 40
to 79 years of age, depending on the associated
risk factor burden in all race-sex groups. Age
continues to be a major determinant of 10-year
ASCVD risk for both men and women. Compared
with the previous risk assessment tool used in
cholesterol guidelines, the inclusion of a stroke
endpoint and use of race-speciﬁc coefﬁcients permit
identiﬁcation of at-risk African Americans and non-
Hispanic white women at much younger ages and
lower risk factor levels.
CONCLUSIONS These data provide context of speciﬁc
risk factor levels and groups of individuals who are
likely to have 10-year ASCVD risk estimates $7.5%.
Age continues to be a major driver of risk, which
highlights the importance of the clinician-patient
discussion before statin therapy is initiated (40).
Low-Risk Diet and Lifestyle Habits in the Primary
Prevention of Myocardial Infarction in Men:
A Population-Based Prospective Cohort Study
A. Åkesson, et al.
BACKGROUND Adherence to a combination of healthy
dietary and lifestyle practices may have an impressive
impact on the primary prevention of myocardial
infarction (MI).
OBJECTIVES The aim of this study was to examine
the beneﬁt of combined low-risk diet and healthy
lifestyle practices on the incidence of MI in men.
METHODS The population-based, prospective cohort
of Swedish men comprised 45- to 79-year-old men
who completed a detailed questionnaire on diet and
lifestyle at baseline in 1997. In total, 20,721 men with
no history of cancer, cardiovascular disease,
diabetes, hypertension, or high cholesterol levels
were followed through 2009. Low-risk behavior
included 5 factors: a healthy diet (top quintile of
Recommended Food Score), moderate alcohol
consumption (10 to 30 g/day), no smoking, being
physically active (walking/bicycling $40 min/dayand exercising $1 h/week), and having no abdominal
adiposity (waist circumference <95 cm).
RESULTS During 11 years of follow-up, we ascertained
1,361 incident cases of MI. The low-risk dietary choice
together with moderate alcohol consumption was
associated with a relative risk of 0.65 (95%
conﬁdence interval [CI]: 0.48 to 0.87) compared with
men having 0 of 5 low-risk factors. Men having all 5
low-risk factors compared with those with 0 low-risk
factors had a relative risk of 0.14 (95% CI: 0.04 to
0.43). This combination of healthy behaviors,
present in 1% of the men, could prevent 79% (95%
CI: 34% to 93%) of the MI events on the basis of the
study population.
CONCLUSIONS Almost 4 of 5 MIs in men may be
preventable with a combined low-risk behavior (41).Impact of Long-Term Burden of Excessive
Adiposity and Elevated Blood Pressure From
Childhood on Adulthood Left Ventricular
Remodeling Patterns: The Bogalusa Heart Study
C.-C. Lai, et al.
BACKGROUND Cardiovascular risk factors are associ-
ated with left ventricular hypertrophy (LVH), but little
is known regarding related impact of longitudinal
measures of childhood adiposity and LV hemody-
namic variables.
OBJECTIVES The aim of this study was to examine
the impact of cumulative long-term burden and trends
of excessive adiposity and elevated blood pressure
(BP) during childhood on adulthood LVH and LV
geometric remodeling patterns.
METHODS This longitudinal study consisted of 1,061
adults, age 24 to 46 years, who had been examined 4 or
more times for body mass index (BMI) and BP starting in
childhood, with a mean follow-up of 28.0 years. The
area under the curve (AUC) was calculated as a
measure of long-term burden (total AUC) and trends
(incremental AUC) of BMI and BP from childhood to
adulthood. Four LV geometric types were deﬁned—
normal, concentric remodeling (CR), eccentric
hypertrophy (EH), and concentric hypertrophy (CH)—
all on the basis of LV mass indexed for body height
(m2.7) and relative wall thickness.
RESULTS Higher values of BMI and systolic and dia-
stolic BP in childhood and adulthood, as well as total
AUC and incremental AUC, were all signiﬁcantly
associated with higher LV mass index and LVH,
adjusted for race, sex, and age. In addition, higher
values of BMI and BP in childhood and adulthood,
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associated with EH and CH but not with CR. Impor-
tantly, all of these measures of BMI had a consistently
and signiﬁcantly greater inﬂuence on EH than did
measures of BP.
CONCLUSIONS These ﬁndings indicate that the
adverse inﬂuence of excessive adiposity and elevated
BP levels on LVH begins in childhood (42).
Aspirin Therapy in Primary Cardiovascular
Disease Prevention: A Position Paper of the
European Society of Cardiology
Working Group on Thrombosis
S. Halvorsen, et al.
Although the use of oral anticoagulants (vitamin K
antagonists) has been abandoned in primary
cardiovascular prevention due to lack of a favorable
beneﬁt-to-risk ratio, the indications for aspirin use in
this setting continue to be a source of major debate,
with major international guidelines providing
conﬂicting recommendations. Here, we review the
evidence in favor and against aspirin therapy in
primary prevention based on the evidence
accumulated so far, including recent data linking
aspirin with cancer protection. While awaiting the
results of several ongoing studies, we argue for a
pragmatic approach to using low-dose aspirin in
primary cardiovascular prevention and suggest its use
in patients at high cardiovascular risk, deﬁned as $2
major cardiovascular events (death, myocardial
infarction, or stroke) projected per 100 person-years,
who are not at increased risk of bleeding (43).
Spironolactone Reduces Cardiovascular and
Cerebrovascular Morbidity and Mortality in
Hemodialysis Patients
Y. Matsumoto, et al.
OBJECTIVES This study sought to assess whether
spironolactone treatment reduces the high incidence
of cardiovascular and cerebrovascular (CCV) morbidity
and mortality in hemodialysis (HD) patients.
BACKGROUND Aldosterone receptor blockers reduce
cardiac-related events, but the efﬁcacy of the agents
in HD patients is unclear.
METHODS A 3-year randomized trial involving 5
clinics was performed. Of the 309 oligoanuric HD
patients enrolled in the study, 157 patients were
randomly assigned to receive 25 mg/day of
spironolactone without any restriction on dietary
potassium intake (treatment group), and 152 patientswere assigned to a control group. The primary
outcome was a composite of death from CCV events
or hospitalization for CCV events, and the secondary
outcome was death from all causes.
RESULTS During the 3-year follow-up, the primary
outcome occurred in 5.7% of patients in the
treatment group and in 12.5% of patients in the
control group. Hazard ratios (HRs) for the primary
outcome for treatment were 0.404 (95% conﬁdence
interval [CI]: 0.202 to 0.809; p ¼ 0.017) and 0.379
(95% CI: 0.173 to 0.832; p ¼ 0.016) before and after
adjustment, respectively. The secondary outcome
was signiﬁcantly reduced in the treatment group
compared with the control group (6.4% vs. 19.7%;
HRs: 0.355 [95% CI: 0.191 to 0.662; p ¼ 0.002] and
0.335 [95% CI: 0.162 to 0.693; p ¼ 0.003] before and
after adjustment, respectively). Gynecomastia or
breast pain was reported in 16 patients (10.2%) in the
treatment group. Serious hyperkalemia led to
treatment discontinuation in 3 patients (1.9%).
CONCLUSIONS Aldosterone receptor blockade using
spironolactone may substantially reduce the risk of
both CCV morbidity and death among HD patients;
however, larger-scale studies are recommended to
further conﬁrm its efﬁcacy. (Effects of Spironolactone
on Cardio- and Cerebrovascular Morbidity and
Mortality in Hemodialysis Patients; NCT01687699) (44).
Angiotensin-Converting Enzyme Inhibitor,
Angiotensin Receptor Blocker Use, and Mortality
in Patients With Chronic Kidney Disease
M.Z. Molnar, et al.
OBJECTIVES The study objective was to assess the
association between angiotensin-converting enzyme
inhibitor (ACEI)/angiotensin receptor blocker (ARB)
use and mortality in patients with chronic kidney
disease (CKD).
BACKGROUND There is insufﬁcient evidence about
the association of ACEI or ARBs with mortality in pa-
tients with CKD.
METHODS A logistic regression analysis was used to
calculate the propensity of ACEI/ARB initiation in
141,413 U.S. veterans with nondialysis CKD who were
previously unexposed to ACEI/ARB treatment. We
examined the association of ACEI/ARB administration
with all-cause mortality in patients matched by
propensity scores using the Kaplan-Meier method
and Cox models in “intention-to-treat” analyses and
in generalized linear models with binary outcomes
and inverse probability of treatment weights in “as-
treated” analyses.
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604RESULTS The age of the patients at baseline was 75 
10 years, 8% of patients were black, and 22% were
diabetic. ACEI/ARB administration was associated
with a signiﬁcantly lower risk of mortality both in the
intention-to-treat analysis (hazard ratio: 0.81, 95%
conﬁdence interval: 0.78 to 0.84; p < 0.001) and the
as-treated analysis with inverse probability of
treatment weights (odds ratio: 0.37, 95% conﬁdence
interval: 0.34 to 0.41; p < 0.001). The association of
ACEI/ARB treatment with lower risk of mortality was
present in all examined subgroups.
CONCLUSIONS In this large contemporary cohort of
nondialysis-dependent patients with CKD, ACEI/
ARB administration was associated with greater
survival (45).Cardiovascular Disease Mortality in
Asian Americans
P.O. Jose, et al.
BACKGROUND Asian Americans are a rapidly growing
racial/ethnic group in the United States. Our current
understanding of Asian-American cardiovascular
disease mortality patterns is distorted by the
aggregation of distinct subgroups.
OBJECTIVES The purpose of the study was to
examine heart disease and stroke mortality rates in
Asian-American subgroups to determine racial/ethnic
differences in cardiovascular disease mortality
within the United States.
METHODS We examined heart disease and stroke
mortality rates for the 6 largest Asian-American
subgroups (Asian Indian, Chinese, Filipino, Japanese,
Korean, and Vietnamese) from 2003 to 2010. U.S.
death records were used to identify race/ethnicity
and cause of death by International Classiﬁcation
of Diseases-10th revision coding. Using both U.S.
Census data and death record data, standardized
mortality ratios (SMRs), relative SMRs (rSMRs), and
proportional mortality ratios were calculated for each
sex and ethnic group relative to non-Hispanic whites
(NHWs).
RESULTS In this study, 10,442,034 death records were
examined. Whereas NHW men and women had the
highest overall mortality rates, Asian Indian men and
women and Filipino men had greater proportionate
mortality burden from ischemic heart disease. The
proportionate mortality burden of hypertensive heart
disease and cerebrovascular disease, especially hem-
orrhagic stroke, was higher in every Asian-American
subgroup compared with NHWs.CONCLUSIONS The heterogeneity in cardiovascular
disease mortality patterns among diverse Asian-
American subgroups calls attention to the need
for more research to help direct more speciﬁc treat-
ment and prevention efforts, in particular with
hypertension and stroke, to reduce health disparities
for this growing population (46).Vaccine for Atherosclerosis
P.K. Shah, et al.
Atherosclerosis is an immune-mediated inﬂammatory
disease of the arterial wall, with both the innate and
adaptive immune systems responding to many
endogenous and exogenous antigens. Both pro-
atherogenic as well as atheroprotective roles have been
identiﬁed for the immune system in atherosclerosis.
Hence, it is conceivable that an immunomodulatory
strategy via active immunization against many of these
antigens could potentially alter the natural history
of atherosclerosis. This review discusses: 1) the com-
plex role of important components of the innate
and adaptive immune systems in atherogenesis; 2)
the nature of many antigens that have been tested
successfully in vaccine formulations to reduce atheros-
clerosis in pre-clinical experimental models; and 3) the
potential opportunities and challenges for clinical
application of vaccination for atherosclerosis in the
future (47).Do Current Clinical Trials Meet Society’s Needs?
A Critical Review of Recent Evidence
S.J. Pocock, et al.
This paper describes some important controversies
regarding the current state of clinical trials research
in cardiology. Topics covered include the inadequacy
of trial research on medical devices, problems with
industry-sponsored trials, the lack of head-to-head
trials of new effective treatments, the need for wiser
handling of drug safety issues, the credibility (or lack
thereof) of trial reports in medical journals, problems
with globalization of trials, the role of personalized
(stratiﬁed) medicine in trials, the need for new
trials of old drugs, the need for trials of treatment
withdrawal, the importance of pragmatic trials
of treatment strategies, and the limitations of
observational comparative effectiveness studies. All
issues are illustrated by recent topical trials in
cardiology. Overall, we explore the extent to which
clinical trials, as currently practiced, are successful in
meeting society’s expectations (48).
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605Trends in Acute Myocardial Infarction in
Young Patients and Differences by Sex and Race,
2001 to 2010
A. Gupta, et al.
BACKGROUND Various national campaigns launched
in recent years have focused on young women with
acute myocardial infarctions (AMIs). Contemporary
longitudinal data about sex differences in clinical
characteristics, hospitalization rates, length of stay
(LOS), and mortality have not been examined.
OBJECTIVES This study sought to determine sex dif-
ferences in clinical characteristics, hospitalization
rates, LOS, and in-hospital mortality by age group and
race among young patients with AMIs using a large
national dataset of U.S. hospital discharges.
METHODS Using the National Inpatient Sample, clin-
ical characteristics, AMI hospitalization rates, LOS,
and in-hospital mortality were compared for patients
with AMI across ages 30 to 54 years, dividing them
into 5-year subgroups from 2001 to 2010, using
survey data analysis techniques.
RESULTS A total of 230,684 hospitalizations were
identiﬁed with principal discharge diagnoses of AMI in
30- to 54-year-old patients from Nationwide Inpatient
Sample data, representing an estimated 1,129,949
hospitalizations in the United States from 2001 to
2010. No statistically signiﬁcant declines in AMI
hospitalization rates were observed in the age
groups <55 years or stratiﬁed by sex. Prevalence of
comorbidities was higher in women and increased
among both sexes through the study period. Women
had longer LOS and higher in-hospital mortality than
men across all age groups. However, observed in-
hospital mortality declined signiﬁcantly for women
from 2001 to 2010 (from 3.3% to 2.3%, relative
change 30.5%; p for trend < 0.0001) but not for men
(from 2% to 1.8%, relative change 8.6%; p for
trend ¼ 0.60).
CONCLUSIONS AMI hospitalization rates for young
people have not declined over the past decade. Young
women with AMIs have more comorbidity, longer LOS,
and higher in-hospital mortality than young men,
although their mortality rates are decreasing (49).CARDIAC FAILURE
Pre-Clinical Diastolic Dysfunction
S.-H. Wan, et al.
Pre-clinical diastolic dysfunction (PDD) has been broadly
deﬁned as left ventricular diastolic dysfunction withoutthe diagnosis of congestive heart failure (HF) and
with normal systolic function. PDD is an entity
that remains poorly understood, yet has deﬁnite clinical
signiﬁcance. Although few original studies have
focused on PDD, it has been shown that PDD is
prevalent, and that there is a clear progression from
PDD to symptomatic HF including dyspnea, edema,
and fatigue. In diabetic patients and in patients with
coronary artery disease or hypertension, it has been
shown that patients with PDD have a signiﬁcantly
higher risk of progression to heart failure and death
compared with patients without PDD. Because of these
ﬁndings and the increasing prevalence of the heart
failure epidemic, it is clear that an understanding of
PDD is essential to decreasing patients’ morbidity and
mortality. This review will focus on what is known
concerning pre-clinical diastolic dysfunction, including
deﬁnitions, staging, epidemiology, pathophysiology,
and the natural history of the disease. In addition,
given the paucity of trials focused on PDD treatment,
studies targeting risk factors associated with the
development of PDD and therapeutic trials for heart
failure with preserved ejection fraction will be
reviewed (50).Noncardiac Comorbidities in Heart Failure With
Reduced Versus Preserved Ejection Fraction
R.J. Mentz, et al.
Heart failure patients are classiﬁed by ejection fraction
(EF) into distinct groups: heart failure with preserved
ejection fraction (HFpEF) or heart failure with reduced
ejection fraction (HFrEF). Although patients with heart
failure commonly have multiple comorbidities that
complicate management and may adversely affect
outcomes, their role in the HFpEF and HFrEF groups
is not well-characterized. This review summarizes
the role of noncardiac comorbidities in patients with
HFpEF versus HFrEF, emphasizing prevalence, under-
lying pathophysiologic mechanisms, and outcomes.
Pulmonary disease, diabetes mellitus, anemia, and
obesity tend to be more prevalent in HFpEF patients,
but renal disease and sleep-disordered breathing
burdens are similar. These comorbidities similarly
increase morbidity and mortality risk in HFpEF and
HFrEF patients. Common pathophysiologic mechanisms
include systemic and endomyocardial inﬂamma-
tion with ﬁbrosis. We also discuss implications for
clinical care and future HF clinical trial design. The
basis for this review was discussions between
scientists, clinical trialists, and regulatory repre-
sentatives at the 10th Global Cardio Vascular Clinical
Trialists Forum (51).
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606Head-to-Head Comparison of 2 Myocardial
Fibrosis Biomarkers for Long-Term Heart Failure
Risk Stratiﬁcation: ST2 Versus Galectin-3
A. Bayes-Genis, et al.
OBJECTIVES ST2 and galectin-3 (Gal-3) were compared
head-to-head for long-term risk stratiﬁcation in an
ambulatory heart failure (HF) population on top of
other risk factors including N-terminal pro–B-type
natriuretic peptide.
BACKGROUND ST2 and Gal-3 are promising biomarkers
of myocardial ﬁbrosis and remodeling in HF.
METHODS This cohort study included 876 patients
(median age: 70 years, median left ventricular ejection
fraction: 34%). The 2 biomarkers were evaluated
relative to conventional assessment (11 risk factors)
plus N-terminal pro–B-type natriuretic peptide in
terms of discrimination, calibration, and reclassiﬁca-
tion analysis. Endpoints were 5-year all-cause and
cardiovascular mortality, and the combined all-cause
death/HF hospitalization.
RESULTS During a median follow-up of 4.2 years
(5.9 for alive patients), 392 patients died. In bivariate
analysis, Gal-3 and ST2 were independent variables
for all endpoints. In multivariate analysis, only
ST2 remained independently associated with
cardiovascular mortality (hazard ratio: 1.27, 95%
conﬁdence interval [CI]: 1.05 to 1.53, p ¼ 0.014).
Incorporation of ST2 into a full-adjusted model for
all-cause mortality (including clinical variables and
N-terminal pro–B-type natriuretic peptide) improved
discrimination (C-statistic: 0.77, p ¼ 0.004) and
calibration, and reclassiﬁed signiﬁcantly better
(integrated discrimination improvement: 1.5, 95% CI:
0.5 to 2.5, p ¼ 0.003; net reclassiﬁcation index: 9.4,
95% CI: 4.8 to 14.1, p < 0.001). Incorporation of Gal-3
showed no signiﬁcant increase in discrimination or
reclassiﬁcation and worse calibration metrics. On
direct model comparison, ST2 was superior to Gal-3.
CONCLUSIONS Head-to-head comparison of ﬁbrosis
biomarkers ST2 and Gal-3 in chronic HF revealed
superiority of ST2 over Gal-3 in risk stratiﬁcation.
The incremental predictive contribution of Gal-3 to
existing clinical risk factors was trivial (52).
Intestinal Blood Flow in Patients With Chronic
Heart Failure: A Link With Bacterial Growth,
Gastrointestinal Symptoms, and Cachexia
A. Sandek, et al.
BACKGROUND Blood ﬂow in the intestinal arteries is
reduced in patients with stable heart failure (HF) andrelates to gastrointestinal (GI) symptoms and cardiac
cachexia.
OBJECTIVES The aims of this study were to measure
arterial intestinal blood ﬂow and assess its role in
juxtamucosal bacterial growth, GI symptoms, and
cachexia in patients with HF.
METHODS A total of 65 patients and 25 controls
were investigated. Twelve patients were cachectic.
Intestinal blood ﬂow and bowel wall thickness were
measured using ultrasound. GI symptoms were
documented. Bacteria in stool and juxtamucosal
bacteria on biopsies taken during sigmoidoscopy
were studied in a subgroup by ﬂuorescence in situ
hybridization. Serum lipopolysaccharide antibodies
were measured.
RESULTS Patients showed 30% to 43% reduced mean
systolic blood ﬂow in the superior and inferior
mesenteric arteries and celiac trunk (CT) compared
with controls (p < 0.007 for all). Cachectic patients
had the lowest blood ﬂow (p < 0.002). Lower blood
ﬂow in the superior mesenteric artery and CT was
correlated with HF severity (p < 0.04 for all). Patients
had more feelings of repletion, ﬂatulence, intestinal
murmurs, and burping (p < 0.04). Burping and nausea
or vomiting were most severe in patients with
cachexia (p < 0.05). Patients with lower CT blood
ﬂow had more abdominal discomfort and immuno-
globulin A–antilipopolysaccharide (r ¼ 0.76, p < 0.02).
Antilipopolysaccharide response was correlated with
increased growth of juxtamucosal but not stool bac-
teria. Patients with intestinal murmurs had greater
bowel wall thickness of the sigmoid and descending
colon, suggestive of edema contributing to GI symp-
toms (p < 0.05). In multivariate regression analysis,
lower blood ﬂow in the superior mesenteric artery,
CT (p < 0.04), and inferior mesenteric artery (p ¼
0.056) was correlated with the presence of cardiac
cachexia.
CONCLUSIONS Intestinal blood ﬂow is reduced in
patients with HF. This may contribute to juxtamucosal
bacterial growth and GI symptoms in patients with
advanced HF complicated by cachexia (53).Prognostic Value of Elevated Levels of Intestinal
Microbe-Generated Metabolite Trimethylamine-
N-Oxide in Patients With Heart Failure:
Reﬁning the Gut Hypothesis
W.H. Wilson Tang, et al.
BACKGROUND Altered intestinal function is preva-
lent in patients with heart failure (HF), but its role in
adverse outcomes is unclear.
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607OBJECTIVES This study investigated the potential
pathophysiological contributions of intestinal micro-
biota in HF.
METHODS We examined the relationship between
fasting plasma trimethylamine-N-oxide (TMAO) and
all-cause mortality over a 5-year follow-up in 720
patients with stable HF.
RESULTS The median TMAO level was 5.0 mM, which
was higher than in subjects without HF (3.5 mM; p <
0.001). There was modest but signiﬁcant correlation
between TMAO concentrations and B-type natriuretic
peptide (BNP) levels (r ¼ 0.23; p < 0.001). Higher
plasma TMAO levels were associated with a 3.4-fold
increased mortality risk. Following adjustments for
traditional risk factors and BNP levels, elevated
TMAO levels remained predictive of 5-year mortality
risk (hazard ratio [HR]: 2.2; 95% CI: 1.42 to 3.43; p <
0.001), as well as following the addition of estimated
glomerular ﬁltration rate to the model (HR: 1.75; 95%
CI: 1.07 to 2.86; p < 0.001).
CONCLUSIONS High TMAO levels were observed in
patients with HF, and elevated TMAO levels por-
tended higher long-term mortality risk independent of
traditional risk factors and cardiorenal indexes (54).
The Use of Digoxin in Patients With Worsening
Chronic Heart Failure: Reconsidering an Old Drug
to Reduce Hospital Admissions
A.P. Ambrosy, et al.
Digoxin is the oldest cardiac drug still in contemporary
use, yet its role in the management of patients with
heart failure (HF) remains controversial. A puriﬁed
cardiac glycoside derived from the foxglove plant,
digoxin increases ejection fraction, augments cardiac
output, and reduces pulmonary capillary wedge
pressure without causing deleterious increases in heart
rate or decreases in blood pressure. Moreover, it is also
a neurohormonal modulator at low doses. In the
pivotal DIG (Digitalis Investigation Group) trial,
digoxin therapy was shown to reduce all-cause and
HF-speciﬁc hospitalizations but had no effect on
survival. With the discovery of neurohormonal
blockers capable of reducing mortality in HF with
reduced ejection fraction, the results of the DIG trial
were viewed as neutral, and the use of digoxin
declined precipitously. Although modern drug and
device-based therapies have dramatically improved
the survival of ambulatory patients with HF,
outcomes for patients with worsening chronic HF,
deﬁned as deteriorating signs and symptoms on
standard therapy often leading to unscheduled clinicor emergency department visits or hospitalization,
have largely remained unchanged over the past 2
decades. The available data suggest that a therapeutic
trial of digoxin may be appropriate in patients
with worsening chronic heart failure who remain
symptomatic (55).Current Evidence on Treatment of Patients With
Chronic Systolic Heart Failure and Renal
Insufﬁciency: Practical Considerations From
Published Data
K. Damman, et al.
Chronic kidney disease (CKD) is increasingly prevalent
in patients with chronic systolic heart failure.
Therefore, evidence-based therapies are more and
more being used in patients with some degree of
renal dysfunction. However, most pivotal randomized
clinical trials speciﬁcally excluded patients with
(severe) renal dysfunction. The beneﬁt of these
evidence-based therapies in this high-risk patient
group is largely unknown. This paper reviews data
from randomized clinical trials in systolic heart
failure and the interactions between baseline renal
dysfunction and the effect of randomized treatment.
It highlights that most evidence-based therapies show
consistent outcome beneﬁt in patients with moderate
renal insufﬁciency (stage 3 CKD), whereas there are
very scarce data on patients with severe (stage 4 to 5
CKD) renal insufﬁciency. If any, the outcome beneﬁt
might be even greater in stage 3 CKD compared with
those with relatively preserved renal function.
However, prescription of therapies should be
individualized with consideration of possible harm
and beneﬁt, especially in those with stage 4 to 5 CKD
where limited data are available (56).Inotropes
G.S. Francis, et al.
Inotropes have been fundamental to resuscitation of
acute cardiogenic shock for decades. Heart failure and
cardiogenic shock, in severe cases, are syndromes
characterized in many patients by a reduction in
myocardial contractile force. While inotropes
successfully increase cardiac output, their use has
been plagued by excessive mortality due to increased
tachycardia and myocardial oxygen consumption
leading to arrhythmia and myocardial ischemia. There
is a pressing need for new inotropic agents that avoid
these harmful effects. This review describes the
mechanism of action and the clinical utility of some
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608of the older inotropic agents, which are still commonly
used, and provides an update for physicians on the
development of newer inotropic drugs. The ﬁeld is
rapidly changing, and it is likely that new agents
will be designed that improve systolic performance
without necessarily increasing the myocardial oxygen
consumption (57).Results of the Destination Therapy Post-Food and
Drug Administration Approval Study With a
Continuous Flow Left Ventricular Assist Device:
A Prospective Study Using the INTERMACS
Registry (Interagency Registry for Mechanically
Assisted Circulatory Support)
U.P. Jorde, et al.
OBJECTIVES A post-approval (PA) study for
destination therapy (DT) was required by the Food
and Drug Administration (FDA) to determine whether
results with the HeartMate (HM) II (Thoratec,
Pleasanton, California) left ventricular assist device
(LVAD) in a commercial setting were comparable to
results during the DT multicenter pivotal clinical trial.
BACKGROUND New device technology developed in
the clinical research setting requires validation in a
real-world setting.
METHODS The PA study was a prospective evaluation
of the ﬁrst 247 HM II patients identiﬁed pre-
operatively as eligible for DT in the national
INTERMACS (Interagency Registry for Mechanically
Assisted Circulatory Support) registry. Patients were
enrolled from January to September 2010 at 61 U.S.
centers and followed for 2 years. A historical
comparison group included patients (n ¼ 133 at 34
centers) enrolled in the primary data cohort in the
DT pivotal trial (TR). Survival rates and adverse
events for the PA group were obtained from the
INTERMACS registry.
RESULTS Baseline characteristics were similar for PA
versus TR. Forty-ﬁve percent of PA patients were in
INTERMACS proﬁles 1 to 2 and 28% were in proﬁle 3.
Adverse events in the PA group were similar or
lower than those in the TR group, including
improvements in device-related infection (0.22 vs.
0.47) and post-operative bleeding requiring surgery
(0.09 vs. 0.23) events per patient-year. Kaplan-Meier
survival at 2 years was 62% (PA group) versus 58%
(TR group). PA group survival at 1 and 2 years was
82  5% and 69  6% for INTERMACS proﬁles 4 to 7
(n ¼ 63) versus 72  3% and 60  4% for proﬁles 1 to
3 (n ¼ 184). The median length of stay after surgery
was reduced by 6 days in the PA group versus the
TR group.CONCLUSIONS Results in a commercial patient care
setting for the DT population supported the original
pivotal clinical trial ﬁndings regarding the efﬁcacy
and risk proﬁle of the HM II LVAD. Survival was
best in patients who were not inotrope-dependent
(INTERMACS proﬁles 4 to 7) (58).Antithrombotic Treatment in Patients With Heart
Failure and Associated Atrial Fibrillation and
Vascular Disease: A Nationwide Cohort Study
M. Lamberts, et al.
OBJECTIVES The aim of this study was to investigate
the impact of atrial ﬁbrillation (AF) and antith-
rombotic treatment on the prognosis in patients with
heart failure (HF) as well as vascular disease.
BACKGROUND HF, vascular disease, and AF are
pathophysiologically related, and understanding
antithrombotic treatment for these conditions is
crucial.
METHODS In hospitalized patients with HF and
coexisting vascular disease (coronary artery disease or
peripheral arterial disease) followed from 1997 to
2009, AF status was categorized as prevalent AF,
incident AF, or no AF. Risk of thromboembolism (TE),
myocardial infarction (MI), and serious bleeding
was assessed by Cox regression models (hazard
ratio [HR] with 95% conﬁdence interval [CI]) with
antithrombotic therapy and AF as time-dependent
variables.
RESULTS A total of 37,464 patients were included
(age, 74.5  10.7 years; 36.3% females) with a mean
follow-up of 3 years during which 20.7% were cate-
gorized as prevalent AF and 17.2% as incident AF.
Compared with vitamin K antagonist (VKA) in preva-
lent AF, VKA plus antiplatelet was not associated with
a decreased risk of TE (HR: 0.91; 95% CI: 0.73 to 1.12) or
MI (HR: 1.11; 95% CI: 0.96 to 1.28), whereas bleeding
risk was signiﬁcantly increased (HR: 1.31; 95% CI: 1.09
to 1.57). Corresponding estimates for incident AF were
HRs of 0.77 (95% CI: 0.56 to 1.06), 1.07 (95% CI: 0.89 to
1.28), and 2.71 (95% CI: 1.33 to 2.21) for TE, MI, and
bleeding, respectively. In no AF patients, no statistical
differences were seen between antithrombotic thera-
pies in TE or MI risk, whereas bleeding risk was
signiﬁcantly increased for VKA with and without
single-antiplatelet therapy.
CONCLUSIONS In AF patients with coexisting HF and
vascular disease, adding single-antiplatelet therapy to
VKA therapy is not associated with additional beneﬁt
in thromboembolic or coronary risk, but notably
increased bleeding risk (59).
J A C C V O L . 6 5 , N O . 6 , 2 0 1 5 Fuster
F E B R U A R Y 1 7 , 2 0 1 5 : 5 8 6 – 6 1 4 Highlights of the Year
609Extracorporeal Membrane Oxygenation in
Cardiopulmonary Disease in Adults
D. Abrams, et al.
The use of extracorporeal membrane oxygenation
(ECMO) for both respiratory and cardiac failure in
adults is evolving rapidly. Advances in technology and
accumulating data are spurring greater interest and
explosive growth in ECMO worldwide. Expanding
indications and novel strategies are being used. Yet
the use of ECMO outpaces the data. The promise of a
major paradigm shift for the treatment of respiratory
and cardiac failure is tempered by a need for evidence
to support many current and potential future uses.
The authors review cannulation strategies, indications,
and evidence for ECMO in respiratory and cardiac
failure in adults as well as potential applications and
the impact they may have on current treatment
paradigms (60).Clinical Impact of Atrial Fibrillation in Patients
With the HeartMate II Left Ventricular Assist
Device
A.D. Enriquez, et al.
BACKGROUND Atrial ﬁbrillation (AF) is common in
patients with the HeartMate II (HMII) left ventricular
assist device (LVAD), but the impact of AF on clinical
outcomes is uncertain.
OBJECTIVES This study sought to determine the ef-
fect of AF on outcomes in patients with the HMII
LVAD.
METHODS Records of 106 patients who underwent
HMII implantation at a single center were reviewed.
The associations of paroxysmal atrial ﬁbrillation (PAF)
and persistent atrial ﬁbrillation (PeAF) with survival,
heart failure (HF) hospitalization, bleeding, and
thromboembolism were examined using Kaplan-Meier
survival analysis and Cox proportional hazards
regression.
RESULTS Mean age was 56.6  11.4 years, 87.7% of the
implants were intended as a bridge to transplantation,
and median length of support was 217 days (range: 1 to
952 days). AF was present in 55 patients (51.9%); 36 pa-
tients (34.0%) had PAF and 19 (17.9%) had
PeAF. Twenty-one patients (19.8%) died, and 18 (17.0%)
were hospitalized for HF. There were 0.75 major
bleeding events and 0.28 thromboembolic events
per patient year of follow-up. PAF was not associated
with increased mortality, HF hospitalization,
bleeding, or thromboembolism. PeAF, however, was an
independent predictor of the composite endpoint ofdeath or HF hospitalization (hazard ratio: 3.54; 95%
conﬁdence interval: 1.52 to 8.25; p < 0.01). Although
there was no increase in bleeding or throm-
boembolism, patients with AF had thromboembolic
events at higher international normalized ratios (INRs).
CONCLUSIONS Although PAF is not associated with
worse outcomes in patients with the HMII LVAD, PeAF
may be associated with increased mortality and HF
hospitalization. Patients with AF also may have
thromboembolic events at higher INR levels (61).Survival Beneﬁt From Transplantation in Patients
Listed for Heart Transplantation in the United States
T.P. Singh, et al.
OBJECTIVES The aim of this study was to assess the
survival beneﬁt from heart transplantation (HT),
deﬁned as reduction in the risks for 90-day and 1-year
mortality on undergoing HT close to listing, in
candidates stratiﬁed by their risk for waiting list
mortality.
BACKGROUND Among patients listed for HT, those
at higher risk for death without transplantation are
also at higher risk for early post-transplantation
mortality.
METHODS All patients age $18 years listed for HT in
the United States from 2007 to 2010 were analyzed. A
model was developed to predict the risk for waiting list
mortality within 90 days, and listed patients were
stratiﬁed into 10 risk groups (deciles). All groups were
followed for 1 year to assess cumulative 1-year
mortality while on the waiting list. Models of 90-day
and 1-year post-transplantation mortality were
developed using recipient data, and these risks were
estimated at listing in all listed candidates.
RESULTS Of 10,159 patients listed for HT, 596 (5.9%)
died within 90 days and 1,054 (10.4%) within 1 year
without undergoing transplantation. Of 5,720 re-
cipients of transplants with 1-year follow-up, 576
(10.1%) died within 1 year. The risk for death while on
the waiting list within 90 days increased from 1.6%
to 19% across the 10 risk groups. The survival
beneﬁt from HT increased progressively with higher
risk for death without transplantation (p < 0.001 for
trend), but there was no beneﬁt in the ﬁrst 6 risk
groups.
CONCLUSIONS The risk for waiting list mortality
varies considerably among HT candidates. Although
the survival beneﬁt of HT generally increases with
increasing risk for waiting list mortality, there is no
measurable beneﬁt in many candidates at the lower
end of the risk spectrum (62).
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610CARDIOMYOPATHIES
The MOGE(S) Classiﬁcation of Cardiomyopathy
for Clinicians
E. Arbustini, et al.
Most cardiomyopathies are familial diseases. Cascade
family screening identiﬁes asymptomatic patients and
family members with early traits of disease. The
inheritance is autosomal dominant in a majority
of cases, and recessive, X-linked, or matrilinear in
the remaining. For the last 50 years, cardiomyopathy
classiﬁcations have been based on the mor-
phofunctional phenotypes, allowing cardiologists to
conveniently group them in broad descriptive
categories. However, the phenotype may not always
conform to the genetic characteristics, may not allow
risk stratiﬁcation, and may not provide pre-clinical
diagnoses in the family members. Because genetic
testing is now increasingly becoming a part of clinical
work-up, and based on the genetic heterogeneity,
numerous new names are being coined for the
description of cardiomyopathies associated with muta-
tions in different genes; a comprehensive nosology
is needed that could inform the clinical phenotype
and involvement of organs other than the heart,
as well as the genotype and the mode of inheritance.
The recently proposed MOGE(S) nosology system
embodies all of these characteristics, and describes
the morphofunctional phenotype (M), organ(s)
involvement (O), genetic inheritance pattern (G),
etiological annotation (E) including genetic defect
or underlying disease/substrate, and the functional
status (S) of the disease using both the American
College of Cardiology/American Heart Association
stage and New York Heart Association functional
class. The proposed nomenclature is supported
by a web-assisted application and assists in the
description of cardiomyopathy in symptomatic or
asymptomatic patients and family members in the
context of genetic testing. It is expected that
such a nomenclature would help group cardio-
myopathies on their etiological basis, describe
complex genetics, and create collaborative regis-
tries (63).
Hypertrophic Cardiomyopathy: Present and
Future, With Translation Into Contemporary
Cardiovascular Medicine
B.J. Maron, et al.
Hypertrophic cardiomyopathy (HCM) is a common
inherited heart disease with diverse phenotypic andgenetic expression, clinical presentation, and natural
history. HCM has been recognized for 55 years, but
recently substantial advances in diagnosis and
treatment options have evolved, as well as increased
recognition of the disease in clinical practice.
Nevertheless, most genetically and clinically affected
individuals probably remain undiagnosed, largely free
from disease-related complications, although HCM
may progress along 1 or more of its major disease
pathways (i.e, arrhythmic sudden death risk;
progressive heart failure [HF] due to dynamic left
ventricular [LV] outﬂow obstruction or due to systolic
dysfunction in the absence of obstruction; or atrial
ﬁbrillation with risk of stroke). Effective treatments
are available for each adverse HCM complication,
including implantable cardioverter-deﬁbrillators
(ICDs) for sudden death prevention, heart trans-
plantation for end-stage failure, surgical myectomy
(or selectively, alcohol septal ablation) to alleviate HF
symptoms by abolishing outﬂow obstruction, and
catheter-based procedures to control atrial ﬁbrillation.
These and other strategies have now resulted in a low
disease-related mortality rate of <1%/year. Therefore,
HCM has emerged from an era of misunderstanding,
stigma, and pessimism, experiencing vast changes
in its clinical proﬁle, and acquiring an effective
and diverse management armamentarium. These
advances have changed its natural history, with
prevention of sudden death and reversal of HF,
thereby restoring quality of life with extended (if not
normal) longevity for most patients, and transforming
HCM into a contemporary treatable cardiovascular
disease (64).
Left Ventricular Noncompaction: A Distinct
Cardiomyopathy or a Trait Shared by Different
Cardiac Diseases?
E. Arbustini, et al.
Whether left ventricular noncompaction (LVNC) is a
distinct cardiomyopathy or a morphologic trait shared by
different cardiomyopathies remains controversial.
Current guidelines from professional organizations
recommend different strategies for diagnosing and
treating patients with LVNC. This state-of-the-art review
discusses new insights into the basic mechanisms
leading to LVNC, its clinical manifestations, treatment
modalities, anatomy and pathology, embryology,
genetics, epidemiology, and imaging. Three markers
currently deﬁne LVNC: prominent left ventricular
trabeculae, deep intertrabecular recesses, and a thin
compacted layer. Although new genetic data from mice
and humans supports LVNC as a distinct
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611cardiomyopathy, evidence for LVNC as a shared
morphological trait is not ruled out. Criteria supporting
LVNC as a shared morphological trait may depend on
consensus guidelines from the multiple professional
organizations. Enhanced imaging and increased use of
genetics are both predicted to signiﬁcantly impact our
overall understanding of the basic mechanisms causing
LVNC and its optimal management (65).
Recovery of Echocardiographic Function in
Children With Idiopathic Dilated Cardiomyopathy:
Results From the
Pediatric Cardiomyopathy Registry
M.D. Everitt, et al.
OBJECTIVES This study sought to determine the
incidence and predictors of recovery of normal echo-
cardiographic function among children with idio-
pathic dilated cardiomyopathy (DCM).
BACKGROUND Most children with idiopathic DCM
have poor outcomes; however, some improve.
METHODS We studied children <18 years of age from
the Pediatric Cardiomyopathy Registry who had both
depressed left ventricular (LV) function (fractional
shortening or ejection fraction z-score <–2) and LV
dilation (end-diastolic dimension [LVEDD] z-score >2)
at diagnosis and who had at least 1 follow-up
echocardiogram 30 days to 2 years from the initial
echocardiogram. We estimated the cumulative
incidence and predictors of normalization.
RESULTS Among 868 children who met the inclusion
criteria, 741 (85%) had both echocardiograms. At 2 years,
22% had recovered normal LV function and size; 51%
had died or undergone heart transplantation (median,
3.2 months), and 27% had persistently abnormal echo-
cardiograms. Younger age (hazard ratio [HR]: 0.92; 95%
conﬁdence interval [CI]: 0.88 to 0.97) and lower LVEDD
z-score (HR: 0.78; 95% CI: 0.70 to 0.87) independently
predicted normalization. Nine children (9%) with
normal LV function and size within 2 years of diagnosis
later underwent heart transplantation or died.
CONCLUSIONS Despite marked LV dilation and
depressed function initially, children with idiopathic
DCM can recover normal LV size and function,
particularly those younger and with less LV dilation at
diagnosis. Investigations related to predictors of re-
covery, such as genetic associations, serum markers,
and the impact of medical therapy or ventricular
unloading with assist devices are important next
steps. Longer follow-up after normalization is
warranted as cardiac failure can recur. (Pediatric
Cardiomyopathy Registry; NCT00005391) (66).Contribution of the Diastolic Vortex Ring to
Left Ventricular Filling
P. Martínez-Legazpi, et al.
BACKGROUND Intraventricular ﬂuid dynamics can be
assessed clinically using imaging. The contribution of
vortex structures to left ventricular (LV) diastolic
function has never been quantiﬁed in vivo.
OBJECTIVES This study sought to understand the
impact of intraventricular ﬂow patterns on ﬁlling and
to assess whether impaired ﬂuid dynamics may be a
source of diastolic dysfunction.
METHODS Two-dimensional ﬂow velocity ﬁelds from
color Doppler echocardiographic sequences were ob-
tained in 20 patients with nonischemic dilated
cardiomyopathy (NIDCM), 20 patients with hypertro-
phic cardiomyopathy (HCM), and 20 control healthy
volunteers. Using a ﬂow decomposition method, we
isolated the rotational velocity generated by the
vortex ring from the surrounding ﬂow in the left
ventricle.
RESULTS The vortex was responsible for entering 13 
6% of ﬁlling volume in the control group and 19  8%
in the NIDCM group (p ¼ 0.004), but only 5  5% in the
HCM group (p < 0.0001 vs. controls). Favorable
vortical effects on intraventricular pressure gradients
were observed in the control and NIDCM groups but
not in HCM patients. Differences in chamber sphe-
ricity explained variations in the vortex contribution
to ﬁlling between groups (p < 0.005).
CONCLUSIONS The diastolic vortex is responsible for
entering a signiﬁcant fraction of LV ﬁlling volume at
no energetic or pressure cost. Thus, intraventricular
ﬂuid mechanics are an important determinant of
global chamber LV operative stiffness. Reduced stiff-
ness in NIDCM is partially related to enhanced
vorticity. Conversely, impaired vortex generation is an
unreported mechanism of diastolic dysfunction in
HCM and probably other causes of concentric remod-
eling (67).
Prevention of Anthracycline-Induced Cardiotoxicity:
Challenges and Opportunities
P. Vejpongsa, et al.
Anthracycline compounds are major culprits in
chemotherapy-induced cardiotoxicity, which is the
chief limiting factor in delivering optimal chemo-
therapy to cancer patients. Although extensive efforts
have been devoted to identifying strategies to prevent
anthracycline-induced cardiotoxicity, there is little
consensus regarding the best approach. Recent
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612advances in basic mechanisms of anthracycline-induced
cardiotoxicity provided a uniﬁed theory to explain the
old reactive-oxygen species hypothesis and identiﬁed
topoisomerase 2b as the primary molecular target for
cardioprotection. This review outlines current strategies
for primary and secondary prevention of anthracycline-
induced cardiotoxicity resulting from newly recognized
molecular mechanisms and identiﬁes knowledge gaps
requiring further investigation (68).
Vector Flow Mapping in Obstructive Hypertrophic
Cardiomyopathy to Assess the Relationship of
Early Systolic Left Ventricular Flow and the
Mitral Valve
R. Ro, et al.
BACKGROUND The hydrodynamic cause of systolic
anterior motion of the mitral valve (SAM) is
unresolved.
OBJECTIVES This study hypothesized that echocar-
diographic vector ﬂow mapping, a new echocardio-
graphic technique, would provide insights into the
cause of early SAM in obstructive hypertrophic car-
diomyopathy (HCM).
METHODS We analyzed the spatial relationship of left
ventricular (LV) ﬂow and the mitral valve leaﬂets
(MVL) on 3-chamber vector ﬂow mapping frames,
and performed mitral valve measurements on
2-dimensional frames in patients with obstructive
and nonobstructive HCM and in normal patients.
RESULTS We compared 82 patients (22 obstructive HCM,
23 nonobstructive HCM, and 37 normal) by measuring 164
LV pre- and post-SAM velocity vector ﬂow maps, 82
maximum isovolumic vortices, and 328 2-dimensional
frames. We observed color ﬂow and velocity vector ﬂow
posterior to the MVL impacting them in the early systolic
frames of 95% of obstructive HCM, 22% of nonobstructive
HCM, and 11% of normal patients (p < 0.001). In both pre-
and post-SAM frames, we measured a high angle of
attack >60 of local vector ﬂow onto the posterior surface
of the leaﬂets whether the ﬂow was ejection (59%) or the
early systolic isovolumic vortex (41%). Ricochet of vector
ﬂow, rebounding off the leaﬂet into the cul-de-sac, was
noted in 82% of the obstructed HCM, 9% of
nonobstructive HCM, and none (0%) of the control
patients (p < 0.001). Flow velocities in the LV outﬂow
tract on the pre-SAM frame 1 and 2 mm from the tip of
the anterior leaﬂet were low: 39 and 43 cm/s, respectively.CONCLUSIONS Early systolic ﬂow impacts the poste-
rior surfaces of protruding MVL initiating SAM in
obstructive HCM (69).Peripartum Cardiomyopathy: Predictors of
Recovery and Current State of Implantable
Cardioverter-Deﬁbrillator Use
J. Pillarisetti, et al.
OBJECTIVES The purpose of this study was to iden-
tify the predictors of left ventricular (LV) recovery in
patients with peripartum cardiomyopathy (PPCM)
and to record rates of implantable cardioverter-
deﬁbrillator (ICD) use.
BACKGROUND PPCM is a rare, life-threatening
disease. The use of ICDs has not been clearly
understood in this patient group. Identiﬁcation of
the predictors of persistent LV dysfunction can help
select patients at risk for sudden cardiac death.
METHODS A retrospective study was conducted at 2
academic centers between January 1, 1999, and
December 31, 2012. Clinical and demographic variables
and delivery records of patients with a diagnosis of
PPCM (International Classiﬁcation of Diseases, 9th Revi-
sion code 674.5) were reviewed. Improvement in LV
function was noted from echocardiography reports.
RESULTS The total sample comprised 100 patients,
of whom 55% were African Americans, 39% were
Caucasians, and 6% were Hispanic, with a mean age of
30  6 years. Mean left ventricular ejection fraction
(LVEF) at diagnosis was 28  9%. Forty-two percent of
patients showed improvement in LVEF over a mean
duration of 33  21 months. Postpartum diagnosis
(hazard ratio: 3.0; p ¼ 0.01) and Caucasian/Hispanic
race (hazard ratio: 2.2; p ¼ 0.01) were predictors of
improvement in LVEF. Only 7 of the 58 patients
(12%) who did not have improvement in their LVEF
had an ICD implanted. There were 11 deaths, with a
trend toward higher mortality in those who did not
display improved LV function (15% vs. 5%; p ¼ 0.1).
CONCLUSIONS More than one-third of women with
PPCM improve LV function with delayed recovery
noted in the majority of these patients. Caucasians
and those diagnosed in the postpartum period
appear to be the most likely to recover. The rate of
ICD implantation for primary prevention of sudden
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